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High throughput screening (HTS) is a critical technology in discovery and process 
chemistry.  Typically, HTS has relied on robotic handling of well plates of samples to rapidly 
perform and assess reactions, but novel technologies that take advantage of microfluidic sample 
processing hold potential as alternatives to typical well plate based assays. Droplet based 
microfluidics has opened the door to the execution of millions of reactions on the nanoliter scale 
but has lagged in application to high throughput screening due to limitations in the options for 
analysis of nanoliter samples, which has largely been performed using optical detection.  The 
work described here addresses this analytical challenge, detailing the design and development of 
an integrated microfluidic system for mass activated droplet sorting (MADS). The MADS 
system uses electrospray ionization mass spectrometry (ESI-MS) to analyze the contents of 
nanoliter scale reactions, and microfluidics to both perform these reactions at nanoliter scale and 
sort and recover the droplets in which they were performed. MADS expands the toolbox for 
droplet detection and recovery, broadening the applicability of droplet sorting to protein 
engineering, drug discovery, and diagnostic workflows. 
To demonstrate the utility of the MADS system, it is applied to the process of Directed 
Evolution.  Directed evolution of biocatalytic enzymes enables the design of enzymes that 
perform new catalytic functions, but requires screening thousands of modified enzymes to 
identify mutations favorable to new catalytic functions. In the pursuit of applying MADS sorting 
to biocatalytic reactions in droplets, this work details the development of the microfluidic 
 xv 
devices and molecular biology workflow for the expression of a library of enzyme variants in 
vitro, each in its own 30 nL droplet. Digital droplet polymerase chain reaction (ddPCR) is 
applied to amplify individual DNA copies in microdroplets, overcoming statistical limitations in 
droplet loading using a high throughput fluorescence activated droplet sorting (FADS) system to 
enrich for individual droplets containing amplified DNA. PCR amplified droplet samples are 
paired with droplets of in vitro transcription and translation (ivTT) matrix to create a final library 
of droplets expressing enzymes in vitro. These samples are screened using MADS to 
demonstrate the capability of the system to enrich the best performing enzymes from a pool of 
library variants.   
As proof of concept, a deleterious mutation is introduced into an existing transaminase 
enzyme and this enzyme is then used as the backbone for a 2000 variant enzyme library. Proof of 
concept is demonstrated by enrichment of the original wildtype enzyme from this library, and 
recovery of the original enzyme activity.  The work completed demonstrates the capability of the 
MADS system to screen tens of thousands of enzyme variants, using just a few milliliters of 




Chapter 1: Introduction 
 
1.1 High-Throughput Screening Technologies 
High-throughput screening (HTS) is a core technology in the pharmaceutical industry and 
a critical component of drug discovery and development pipelines.  The label of “High-







, but the terminology tends to vary between applications depending on the 
complexity of the assay and the analytical readout used to assess the result of the experiment.  
Typically, high throughput screening is carried out in multi-well plates (MWP), which were 
introduced in the 1950s
2
 and rose in popularity in the 1970s
3
 as tools to improve the efficiency of 
laboratory experimentation.  These plates have become standardized in size, allowing 
experiments to be carried out in 96, 384, and 1536-well formats by robotic systems as well as by 
hand
3
.  In these formats, reactions are carried out in volumes ranging from 5 to ~300 microliters, 
with each reaction taking place in a single well.  
1.2 The Interplay of Analytical Throughput and Sample Introduction 
In a typical HTS assay, the most significant bottlenecks determining assay throughput are 
analytical throughput and sample processing throughput.  Information rich analytical 
methodologies, such as liquid chromatography (LC), mass spectrometry (MS), nuclear magnetic 
resonance (NMR) spectroscopy, and infrared (IR) spectroscopy, have analytical speeds ranging 
from 30s seconds to 30 min per sample.  As such, these technologies are generally incapable of 




themselves to rapid screening.  As such, most high throughput screens have been carried out 
using photometric spectroscopy, in particular absorbance and fluorescence.  Absorbance and 
fluorescence spectroscopy are comparably information-light relative to their counterparts in the 
analytical toolbox, but the high sensitivity and rapid response times of photodetectors give the 
technique a distinct edge when applied to high throughput analytical assessment.  For example, 




 which readily 
accommodates analytical throughput on the order of one hundred thousand (10
5
) of samples per 
second in flow based formats like flow cytometry.
5
  The introduction of charged coupled devices 
(CCD) for plate imaging has enabled high density plates to be assessed in a single image, 
allowing luminescence, fluorescence and scintillation to be assessed across hundreds of wells 
with a single imaging device.
6
  Given a rapid and sensitive mode of detection, the throughput 
limit is governed by the rate at which samples may be introduced to the analytical detector.   
Scanning a MWP with the appropriate optical configuration allows modern CCD plate 
readers to analyze a 384 well plate in under a minute, allowing for throughputs ranging from 1-
10 samples per second.   At these speeds, tens of thousands of samples may be analyzed per day, 
but this still lags far behind the theoretical limit of photometric assessment. The limitation of 
MWP technology for screening throughput stems from the physical size, separation, and 
positioning of samples in space, which determines the speed with which robotic and imaging 
systems can access these samples. However, faster sample introduction to the detector is possible 
in flow based setups, where serial samples are passed by the detector.  A particularly good 
example of this is fluorescent activated cell sorting (FACS), which was developed in the 1970s 
and combines the liquid handling technology behind ink jet printing
7
 with the rapid analytical 




continuously flowing cell suspension, sample is broken into droplets containing single cells, and 
individual droplets are sorted based on photometric readouts.
8
  FACS systems are capable of 




 samples per second.  This 
innovation demonstrates that given a high analytical acquisition rate, the limit to throughput is 
determined by sample handling and introduction speeds. In FACS, continuous flow of samples to 
a detector allows sample interrogation to proceed up to the throughput limit of detection.   
1.3 Microfluidics for High Throughput Sample Generation and Manipulation 
 The past four decades have seen the rise of automated liquid handling robotics capable 
of addressing each well in a MWP, dispensing volumes ranging from the nanoliter (Caliper Life 
Science SciClone pin tool) to the microliter range.   While this strategy reduces the bottleneck of 
sample generation and allows thousands of well plate reactions to be created and run in concert, 
it simply cannot generate samples at throughputs that approach FACS analytical speeds.  
However, nanoliter scale sample handling is regularly performed in capillary flow-based 
systems, such as those used to manipulate liquid in chromatography systems.   These systems use 
micron scale (microfluidic) channels to mix and transport small volumes with pinpoint accuracy.  
Unfortunately, this form of microfluidic sample handling has been difficult to adapt to HTS 
given the difficulty of maintaining a series of discreet samples in continuous flow.  Switch valve 
configurations such as those used in standard chromatography injection systems allow discreet 
sample plugs to be serially injected and cleared from a capillary flow path but these components 
require large dead volumes to counter carryover and Taylor dispersion
9,10
 between samples.   
Segmented flow has been used in microfluidics to address the challenges of single phase 
microfluidic systems with regards to sample separation, surface fouling, and inefficient mixing
11-
13
. Simple flow-focusing and T-junction microchannel geometries
13-15




to be brought together in capillary flow to form dispersed droplets of one phase “carried” by the 
other.  By using an oil carrier phase that is sufficiently omniphobic with respect to analytes in the 
aqueous phase, each droplet may be treated as an isolated sample.  Typically, fluorocarbon oils 
such as perflourodecalin are used to provide this physical and chemical barrier.  This form of 
microfluidic sample handling is known as “droplet microfluidics.”  
The highly uniform generation of droplets in microfluidics makes this technology a 
potentially attractive alternative to MWPs, as each microdroplet acts as its own separate reactor 
(Figure 1-1 A). Performing chemical reactions in discrete droplet volumes allows for rapid in-
line analysis, much like cell analysis in FACS systems.
14
  This presents an attractive opportunity 
to scale complex liquid handling to speeds that match the true throughput limit of photometric 
assessment.  
 To perform discrete chemistry with droplets, they must be stored, manipulated, and 
analyzed. While the simplest way to store droplets separately is done in-line via micro-channels 
or capillaries, the back pressure generated by fluidic resistance within such systems can be 
problematic.   High throughput screening operations require thousands of samples to be 
manipulated in series, so the use of amphipathic surfactants that prevent droplet coalescence 
have become commonplace and allow droplets to be stored in bulk.
16,17
 Surfactants such as the 
triblock copolymer perfluoropolyether-polyethylene glycol (PFPE-PEG-PFPE, Figure 1-1) 
mimic the function of phospholipid membranes in biological systems and prevent droplet 









Figure 1-1: Chemical structure of PFPE-PEG-PFPE surfactants 
 
Droplet microfluidics enables many of the core functionalities of microplate sample 
manipulation  Advances in microfabrication
18
 have enabled the creation of complex capillary 
geometries in monolithic chips for performing secondary operations on droplets. These have 
been designed to address many of the core functionalities of well plate screening.
14
 In well 
plates, robotic pipetting systems enable the addition of reagent to individual reactions. In droplet 
microfluidics, reagent addition is most commonly achieved by direct injection
19
 or pairwise 
merging
20
 of droplets (Figure 1-2 B).  When placed in series, direct injection allows multiple 
reagents to be added to each droplet in rapid succession. These functions often exceed the 
throughput of robotic handling by an order of magnitude or more.  
In MWP format, small volumes of sample may be recovered for analysis, further 
reactions, or long-term storage. In droplet format, sampling can be performed by splitting 
droplets in flow using microchannel bifurcations
21,22





 Droplet splitting may also be used to perform sample exchange and solid 
phase extractions, allowing selective retention of targeted analytes in droplets via bead based 






Figure 1-2: Unit operations in droplet microfluidics 
Droplet microfluidics enables many of the core functionalities of microplate sample 
manipulation to be replicated in flow.  A) Droplets are generated using flow focusing 
microstructures, creating digital separation of samples in distinct droplets (scale bar 100 µm). B) 
Droplet content may be modified through the addition of reagent to distinct droplets, either by 
droplet pairing or picoinjection (scale bar 300 µm). C) Reactions may be sampled in flow using 
droplet splitting architectures to break droplets into two daughter droplets, creating sample 
replicates (scale bar 100 µm). D) Droplets may be selected and recovered for further analytical 
assessment or statistical enrichment using active and passive sorting techniques like 
dielectrophoresis and magnetophoresis (Scale bar 500 µm). 
 
The confinement of samples in a well plate facilitates easy sample recovery and 
secondary analysis, as well as clear spatial encoding of droplet identities.  Droplets must be 
recovered following primary analytical readout if secondary analysis is necessary. The most 
common strategy for doing so is dielectrophoresis (DEP) where a droplet may be deflected in an 
electric field to exit a device via a selected channel (Figure 1-2 D).
29,30
 This sorting strategy 
operates in a similar manner and throughput to the electrostatic sorting of droplets in FACS, 
allowing droplets to be sorted at throughputs up to 10
5
 samples per second.
31
  Fluorescence 
activated and absorbance activated
32
 droplet screening (FADS and AADS) are robust droplet 
screening techniques employed across a wide range of applications.
29,32-40
  While spatial 






 and droplet microfluidics allows sample handling to begin to approach the 
throughput limits of photometric detection. 
1.4 Analytical Challenges for Microdroplet Interrogation 
 Both droplet microfluidics and traditional MWP screening methodologies are limited in 
utility when coupled with the low information density of photometric detection.  The analytical 
information obtained is simply an analog output on a single channel (photometric intensity) and 
gives little information on the underlying chemistry or biology within the sample without careful 
linkage through assay development. Only reactions that engender a distinct change in 
fluorescence or absorbance may be assessed using MWP readers, and few reactions exhibit these 
properties natively.  As a result, significant research and development has been devoted to the 
discovery and use of fluorescent markers as indicators of chemical or biological activity.  
Advances in fluorescence polarization (FP), Förster resonance energy transfer (FRET) and 
fluorescence quenching have broadened the scope of reactions that may be probed using 
fluorescence,
42
 and have allowed spectroscopic techniques to maintain their dominance in the 
field of HTS.  Unfortunately, these techniques still carry inherent disadvantages, in that they 
rarely probe the reaction of interest directly and suffer from significant risk of off target effects.
43
  
False positives may be caused by unintentional quenching or auto-fluorescence, off target effects 
(such as inhibition or activation of secondary reporter enzymes that produce a visible signal), and 
secondary or unforeseen chemical reactivity or affinity within the assay.   Assay development 
must be undertaken with care, and often industrially relevant reactions prove difficult or 
impossible to link to optical outputs.  In these instances, more information dense analytical 





When information content and targeted compound identification and quantification of 
small molecule analytes is paramount to analytical assessment, liquid chromatography and mass 
spectrometry dominate the laboratory toolbox. Historically, these techniques have not been 
accessible for high throughput screening applications.  LC coupled to ultraviolet (UV) and MS 
detection systems have been adapted to MWP sample format, but the throughput of these 
systems is defined by the throughput of chromatographic separations and switch valve auto 
sampling. Chromatographic separations on analytical columns typically take a minimum of 
several minutes to run and require skilled method development and operation to maximize 
throughput, while switch valve based sample handling systems require significant dead volume 
(in the microliter range) and a serial load-inject workflow that limits the frequency with which 
samples may be introduced to analytical assessment.  This bottleneck has been a significant area 
of research for analytical chemists. Recent developments, such as the use of multiple injections 
in a single experimental run (MISER), have enabled LC separations to be carried out in less than 
one minute per sample, which is a hugely enabling improvement relative to the multiple-minute 
separations of the past  and represent a major step forward in throughput.
44
  
One potential work-around for high information content analytical assessment lies in 
direct analysis of samples without the use of chromatographic separation.  Mass spectrometry is 
a potential candidate for this kind of analysis, due to the ability of MS to rapidly separate and 
detect multiple analytes in the gas phase. Mass spectrometers are comprised of three core parts: 
an ion source, a mass analyzer, and a detector.  The ion source ionizes the analytes in the 
interrogated sample, ejecting them as charged molecules in the gas phase.  The mass analyzer 
uses carefully shaped and focused electric fields to select and separate these gaseous ions based 






 enable high resolution separations of these complex mixtures of ions, as well as the 
selection of a single ions of interest from a mixture.  These separated ions are then sent to the 
detector to give in-depth chemical information on the mass of the analytes within the complex 
mixture. 
 Direct mass spectrometry has historically been limited in throughput by sample cleanup 
and sample introduction throughputs.  Sample cleanup must typically be performed to minimize 
interference from ionization suppressing salts and buffers, but developments such as the Agilent 
Rapidfire, which can incorporate solid phase extraction (SPE) into the sampling workflow and 
rapidly load and inject samples from a MWP, have enabled faster sample injection to MS 
analysis.
46
 More recently, acoustic sample injection (ECHO-MS) has been demonstrated and 
commercialized for direct MS analysis off of a wellplate,
47
 and direct analysis in real time 
(DART-MS) have enabled more rapid sample analysis by MS without significant sample pre-
processing.
48
  These technologies have enabled MS analysis at speeds ranging from 10 s per 
sample to 0.3 s/sample, and have demonstrated the potential for coupling more complex 
analytical assessment to existing MWP technologies.   
1.5 Direct MS Assessment in Droplet Microfluidics 
 Analytical assessment in droplet microfluidics has historically been limited in scope.  
The relative ease of adapting photometric detection to droplet analysis has made it the 
predominant approach in droplet microfluidic development, similar to MWP-based HTS. 
Microscopic sample sizes in droplet systems do not lend themselves to more data rich analytical 
platforms, largely due to the limited volume available for analysis.  The need for greater 
analytical depth is well recognized within the microfluidics research community, and recent 




to picoliter droplet volumes.
49,50
  While chromatography with segmented flow at nanoliter to 
picoliter scales has been more difficult to achieve, recent work from our group has shown facile 
coupling of microchip capillary electrophoresis (CE) to droplet introduction, which enables 
individual separations to be performed at sub-second time scales.
51
  In addition to CE with 
fluorescent detection, Raman spectroscopy has been applied to single cell detection in droplets as 
a detection method that is fast enough to trigger dielectrophoretic sorting of droplets in flow.
52-54
  
Raman spectroscopy allows label-free detection of analyte in droplets and in cells;
55
 however, 
signal error can arise from interference from the oil phase and optical distortion in the droplets. 
Additionally, Raman spectroscopy suffers from low sensitivity without the use of surface 
enhancement or extended analytical timescales, which makes the technique more difficult to 
apply towards complex matrices in which non-specific molecular adsorption to the necessary 
gold and silver nanoparticles can limit analytical utility.
49,53,54
  Absorption spectroscopy has been 
applied in droplet microfluidic workflows in several formats as well,
32,56
 and electrochemical 
detection in droplets has been performed as well.
57
 
Mass spectrometry has also been explored as an analytical method in droplet 
microfluidics.
58-61
  MS is particularly attractive as an approach to droplet analysis for several key 
reasons.  First, MS is commonly coupled to continuous flow separation methods, as is 
exemplified in LC-MS systems.  Ionization techniques, in particular electrospray ionization 
(ESI), may be easily integrated into the fluid path of a microfluidic system and are capable of 
detecting the contents of droplets as small as 60 pL in volume.
61
  After ionization, analytes in a 
mass spectrometer may be separated by the mass analyzer, allowing specific analytes to be 
detected based on their unique mass signature (Figure 1-3).  While a wide variety of mass 





Figure 1-3: Schematic of droplet mass spectrometry 
Droplet Mass spectrometry via electrospray ionization allows individual droplets to be sprayed 
by mass spectrometry as they are infused through a capillary to the ionization source.  As each 
droplet flows to the tip of the electrospray emitter, the liquid within is nebulized and the contents 
are ionized by the high voltage electric field at the tip of the emitter. As the oil in between the 
samples exits the tip, electrospray ceases and the dielectric oil is left un sprayed.  Propelled by 
focused electric fields, the ionized analytes within the droplet enter the mass spectrometer’s mass 
analyzer, where the ionized materials are selected and isolated based on their mass to charge 
ratio and sent to a detector.  The detector outputs an analog signal of ion intensity which, 
depending on the selection mode of the mass analyzer, may correspond to a single selected mass 
of interest (single ion monitoring) or a spectrum of intensities across a scanned mass range. 
 
operate on timescales in the millisecond range,
62
 creating the potential for rapid analytical 
assessment that pairs well with droplets in flow.  Finally, the end point detection of MS utilizes 
electron multipliers, which operate in a manner analogous to PMTs.  The response time of these 
detectors are comparable with PMTs, and as a result, throughput limitation in droplet MS arises 




30 droplet samples have been detected per second using mass spectrometry.
63
 
Despite the potential for MS to be adapted to high throughput screening in droplet flow 
paradigms, state-of-the-art systems have largely been limited to a few hundred samples per 
screen.
58,59
  The label free nature of MS detection, coupled with its compatibility to flow and 
segmented flow based systems, make it an attractive and practical analytical strategy in the 
development of microfluidic systems for high throughput screening.   
1.6 High Throughput Screening for Directed Evolution 
 The use of fluorescent detection for high throughput screening has seen widespread use in 
the areas of drug discovery, probing biological interactions, and cytometry.  These fields lend 
themselves to interrogation by photometric detection, because the output phenomena being 
probed is often a macromolecular response – i.e. a protein interaction that is blocked, a binding 
process that is inhibited, or a change in cell viability.  These phenomena may often be observed 
by using a fluorescent indicator to signal a macromolecular response of interest.  For example, 
the binding of two proteins may be probed for disruption by using a FRET donor or acceptor on 
each binding unit.  
 Unfortunately, systems and reactions of interest in HTS do not always lend themselves to 
interrogation by fluorescent tagging. Synthetic chemistry and biocatalytic processes involving 
the production of a small molecule or metabolite are particularly difficult to track with 
fluorescence.  Tracking catalytic activity is difficult because placing a bulky fluorophore on a 
small molecule substrate can alter the chemical properties of these compounds and in turn, 
impact the way they interact with biological targets of interest.
43
  Even if initial screens are 
possible using creative assay development, hits must often be validated with secondary, more 




 Biocatalytic transformations are of growing import in the field of synthetic chemistry.
64
  
Reactions catalyzed by enzymes in biological systems tend to be highly chemoselective, 
regioselective, and enantioselective.
65
  As such, enzymes have been shown to enable synthetic 
transformations that are often inaccessible or prohibitively costly when performed using 
transition metal catalysis.  Notably, enzymes can perform challenging chemical syntheses under 
comparatively mild conditions, without the use of toxic solvents, high temperatures, or carefully 
controlled reactors.
66,67
  Millions of years of evolution have built these macromolecular 
structures into nature’s chemical factories. Given its expedited access to enantiopure compounds, 
as well as sustainable, process-friendly reaction conditions, biocatalysis has emerged as a highly 
enabling synthetic strategy across the pharmaceutical and agrochemical industries. 
 The greatest drawback to using biocatalysis for chemical synthesis is the process by 
which one goes about identifying optimal enzyme biocatalysts. Enzymes have undergone 
millions of years of evolution to perform a specific task; they are rarely very active outside their 
native substrate scope.  However, in order for the natural world to contend with evolving 
synthetic needs, it has developed ways to rapidly modify its catalysts to fit new and prescient 
activities. Enzymes have been significantly re-programmed to produce novel catalytic outputs 
through the process of evolution.  The synthetic needs of modern chemists operate at timescales 
vastly smaller than the millions of years of evolution required for an organism to restructure an 
enzyme to achieve a new biological purpose. In order to adapt biocatalytic enzymes to prescient 
needs, modern biocatalytic chemists must find ways to rapidly alter the synthetic capabilities of 
enzymes.  This has engendered the field of directed enzyme evolution (DE). 
Directed evolution is the mutation and selection of enzymes for the purpose of creating 




through rational design or untargeted screening (Figure 1-4).  The field was pioneered by 
Frances Arnold and her group at the California Institute of Technology and was recognized with 
the Nobel Prize in chemistry in 2018.
68
  By screening thousands of enzyme variants, researchers 
have created catalysts capable of a remarkable array of transformations.
64-66,69
  These evolved 
biocatalysts are becoming common for use in the industrial production of chemicals ranging 
from biofuels to pharmaceuticals.
70
   
Unfortunately, the process of directed evolution requires laborious/extended screening 
campaigns to identify enzymes that are active against non-native substrates.  The typical enzyme 
evolution workflow involves the expression of a library of enzymes in host cells, followed by the 
separation of each enzyme variant into its own individual well on a plate, induced protein 
expression for each captured colony, and lysis to release the expressed protein into solution.  The 
lysate is then screened for activity on the small molecule of interest.  In industry, a typical round 




 enzyme variants. 
Additionally, an enzyme may undergo more than ten rounds of selection and mutation before a 
sufficiently stable, active, and efficient variant is identified.  While industrial HTS facilities have 
the capability to screen libraries of such magnitude, conventional photometric methods of 
analysis are incompatible with biocatalytic transformations with regard to analytical depth.   
Chemoenzymatic processes typically occur on small molecule substrates and catalytic activity is 
intrinsically tied to the structure of this substrate.  As a result, fluorescent detection becomes 
more challenging to implement, and direct detection by LC-MS or LC-UV is used for reaction 
analysis.   This dependence on LC-based analysis significantly extends the timeline of 





Figure 1-4: The molecular biology workflow of directed evolution 
The core workflow of Directed Evolution follows the same cycle as natural selection and 
evolution.  A parent gene is chosen as the basis for a library of enzyme variants.  This gene is 
mutated to create the library, and each gene is transformed into cells and expressed in cell 
culture.  Individual cells (and therefore enzyme variants) are separated into individual wells on a 
plate.  The cells are cultured and lysed to release protein into solution, and then assayed for 
activity on the target compound.  Hits are analytically assessed and identified, and the genetic 
information coding for those hits becomes the basis for the next round of parent genes.  
  
For cases in which photometric detection may be applied to detect enzyme activity, rapid 
droplet microfluidics-based photometric screening methods have enabled millions of enzymes to 
be screened and sorted in record time.
32,37,40,71-76
 These methods have been groundbreaking for 
the field of biocatalysis and highlight the feasibility of screening for and identifying a new 




detecting catalytic outputs have stymied any effort to adopt these techniques on a broader scale.  
Mass spectrometry-based detection of microfluidic droplet contents represents a potentially 
revolutionary development for advancing HTS of enzymes.  This would enable the rapid 
generation of droplets that contain individual enzymes, as well the ability to test sample activity 




 samples could be assessed in a 
single day, allowing rounds of evolution to be carried out in record time, regardless of the 
substrate. 
1.7 Dissertation Overview 
 Early experiments with MWP based droplet MS screening indicated that enzyme activity 
tracked well with MS signal in direct droplet infusion experiments.
77
  Many of these early 
experiments relied on MWP formats for reaction incubation as well as subsequent MS readout. 
As droplet microfluidics-based sample generation and manipulation became rapidly more 
versatile, novel HTS systems that demonstrate the feasibility of rapid creation and in vitro 
expression of enzyme libraries in droplets have been developed.
40,78,79
   In this context, the aim of 
this thesis work is to demonstrate facile integration of droplet MS into a droplet sorting device, 
while enabling reliable creation and MS assessment of droplets containing expressed enzyme.  
More significantly, this work aims to integrate these two systems for use in the complete 
workflow of directed enzyme evolution.   
In Chapter 2, this work details the development and completion of first component 
system of these aims: mass activated droplet sorting (MADS)
80
.  This is a microfluidic system 
for high-throughput sorting of nanoliter droplets based on direct detection using electrospray 




Figure 1-5: Schematic of the MADS system. 
Mass activated droplet sorting (MADS) begins with the infusion of droplets onto the 
microfluidic device.  On the MADS chip, droplets are re-spaced with carrier oil and split into 
two portions.  The larger of the two portions exits the device and is sprayed at the mass 
spectrometer.  The smaller of the two portions remains on the microfluidic chip where it is 
imaged by a camera and then sorted based off the alignment of the MS and camera signals and 
the MS signal relative to the selection threshold.  Marker droplets infused into the device give a 
shared signal at both the camera and the mass spectrometer that enable accurate alignment of the 
two concurrent data streams. 
 
analyzed by ESI-MS with a portion retained and sorted based on the MS result. We demonstrate 
a throughput of 0.7 samples/s at 98% accuracy and use the system to screen ~15,000 samples in 
6 h.  The hardware, software, and engineering supporting the microfluidic devices at the core of 
our system is also described in depth. In Chapter 3, application of the MADS system is 
demonstrated for directed evolution high-throughput screening.  A microfluidics based workflow 
for performing in vitro expression of large enzyme libraries in droplet samples is detailed.  
Droplet polymerase chain reaction
81
 followed by fluorescent activated droplet sorting is 




Figure 1-6: Schematic of the MADS workflow for directed evolution 
The microfluidic workflow proposed in this thesis for the Directed Evolution of Enzymes in 
nanoliter droplets. The work begins with the production of single droplets of DNA with unique 
sequences coding for enzyme variants using digital PCR (Device 1)  These droplets are then 
sorted by their fluorescence (Device 2) before being paired with in vitro expression reagents to 
express a unique protein in each droplet (Device 3).  After expression and incubation with 
reagents of interest, individual droplets are split, with half of the droplet running to the mass 
spectrometer for analysis and half of the droplet running to a microfluidic sorting device for 
recovery (Device 4).  Droplets are sorted based of the signal from the mass spectrometer, 
recovered, and analyzed for improved enzyme activity.   
 
of a transaminase single site mutation (SSM) library.  Following FADS enrichment, we use 
droplet pairing strategies to combine DNA bearing droplets with in vitro expression materials to 
express each droplet of amplified DNA as a unique transaminase enzyme, captured within a 
single 30 nL droplet.  MADS is used to identify and enrich for winners performing better than a 
positive control parent enzyme (Figure 1-6). 
 In Chapter 4 the critical challenges to the implementation of the MADS system are detailed, 
and future areas of development for droplet mass spectrometry and mass activated droplet 
sorting are highlighted.  Key challenges such as inter-droplet chemical transfer, reaction 
quenching in droplet systems, and the analytical limitations of direct mass spectrometry of 
microfluidic samples are discussed, and areas of further development potential for droplet mass 




Chapter 2: Mass Activated Droplet Sorting (MADS) Enables High Throughput Screening of 
Enzymatic Reactions at Nanoliter Scale  
 
Adapted with permission from Holland-Moritz, et al. Angew. Chem. Int. Ed. 2020, 59, 4470. 
Copyright © Wiley 
. 
2.1 Introduction 
Droplet microfluidics enables experiments to be performed at nanoliter to femtoliter 
scale, increasing throughput and decreasing unit costs of chemical and biological 
experimentation.
77,82
 A decade of research in the field has demonstrated the utility of droplet 







 Dielectrophoretic droplet sorting
30
 has made 
possible the rapid recovery of selected samples for analysis.
29,73,74,89
 The ability of microfluidic 
systems to create, assay, and sort microscale samples is attractive in applications where sample 
preparation and analysis are bottlenecks, e.g. directed evolution of enzymes.  
Active sorting of microfluidic droplets largely relies on optical detection.
49,90
 
Fluorescence activated droplet sorting is most frequently utilized because of its high speed and 
sensitivity. FADS has found use in ultrahigh throughput screening for directed 
evolution.
32,34,37,40,76,91
 Screening large libraries is often the rate-limiting step in biocatalyst 
development, where thousands of enzyme variants must be tested for catalytic activity,
77
 and 
plate based screens are time and resource intensive.  FADS has enabled screening of libraries 




Fluorescence detection requires a reporter molecule, a condition that is difficult to meet 
in many applications.
92,93
 Fluorescent indicators must be carefully selected to ensure that they are 
retained within droplets,
94-96
 do not interfere with the process being investigated, and provide a 
readout dependent only upon the assay of interest. These limitations have restricted the use of 
droplet assays for high throughput biocatalyst screening in industry, where most target analytes 
are small molecule pharmaceuticals that are difficult to adapt to fluorescent assays. For example, 
in developing a transaminase for the production of the pharmaceutical sitagliptin, Savile et. al
66
 
screened nearly 36,000 variants of a transaminase. High performance liquid chromatography 
(HPLC)-MS was used to guide the selection of variants because the transformation (ketone to 
chiral amine) produced no significant change in the optical properties of the substrate and 
product. 
To address the limits of fluorescence based screens, recent work has expanded the 





 and Raman spectroscopy
52,54
 have been employed as 
alternatives to fluorescence detection in droplets. Although these methods have widened the 
range of analytical techniques available for droplet sorting, they too have significant limitations 
in their implementation. Raman spectroscopy allows label-free detection of the target analyte but 
the signal is negatively affected by interference from the oil phase and optical distortion in the 
droplets. Raman additionally suffers low sensitivity without the use of surface enhancement, 
which makes the technique more difficult to apply in complex matrices where non-specific 
molecular adsorption to the necessary metal nanostructures can limit analytical utility.
49,53,54
 
Absorbance spectroscopy offers another unlabeled approach to droplet detection.  




reporters for detection when the target analyte absorbs weakly and when the reaction does not 
result in a sufficient change in absorbance.
32
 Droplet imaging techniques are limited to visible 
characteristics such as size, color, or particle content, none of which are direct methods for 
observing the chemical content of a droplet sample.  
Analysis and sorting of droplets using mass spectrometry would be a valuable addition to 
the methods for droplet sorting. MS offers nearly universal label-free detection with high 
sensitivity and selectivity, as well as the flexibility for multiplexing.  Recent work with ESI
58-
61,77,99
 and matrix-assisted laser desorption/ionization (MALDI) MS
100-102
 has shown that MS can 
be used for droplet analysis; however, sample destruction by ESI has been an obstacle to 
coupling it to microfluidic droplet sorting. 
Mass Activated Droplet Sorting (MADS) is a technique that couples droplet ESI-MS to 
DEP sorting. MADS is capable of sorting thousands of nanoliter droplets at ~0.7 samples/s based 
on their MS signal with up to 98% accuracy. The method relies on a programmable sorting 
algorithm that enables MS-based sample identification and dynamic thresholding.
103
 
The utility of this system is first demonstrated by sorting a pool of droplets based on 1-
(pyridin-3-yl)ethan-1-amine (“pyridinyl amine”) concentration. Following this, we screen 
samples for activity of the transaminase ATA-117 after in vitro expression in droplets. We enrich 
droplets based on their conversion of the non-native substrate 1-(imidazo[2,1-b]thiazol-6-yl) 
propan-2-amine (“ATA Substrate”, Scheme 2-1). This screen would not be feasible by either 
FADS or AADS methodology, illustrating the potential of MADS to screen reactions that are not 





Scheme 2-1: ATA117 conversion of 1-(imidazo[2,1-b]thiazol-6-yl) propan-2-amine 
The reaction for the transformation of the non‐native ATA Substrate into its corresponding ATA 
product ketone is catalyzed by ATA 117. 
 
2.2 Experimental - Mass Activated Droplet Sorting 
In order to perform Mass Spectrometry based sorting of microfluidic droplets, we had to 
design and build a microfluidic system capable of both reading and sorting nanoliter scale 
droplets on a single device.  To achieve this, we built the microfluidic devices, optimized their 
operation, and integrated the software control systems that would make and execute microfluidic 
sorting decisions. 
2.2.1 Microfluidic Device Fabrication 
In order to perform microfluidic functions, we designed and built a series of microfluidic 
devices to perform both droplet mass spectrometry, and reagent addition to microfluidic droplets. 
Microfluidic devices were fabricated using standard soft lithography techniques.
104
  Devices 
were designed using AutoCAD software (Autodesk) and printed onto mylar film masks at 
25000-50000 dpi (Fineline Imaging).  Using these masks, SU-8 2075 (Microchem Corp) was 
patterned (Figure 2-1) to a depth of 200 µm on a 7.62 cm diameter silicon wafer (University 
Wafer).  Poly dimethyl siloxane (PDMS) (Curbell Plastics) was prepared in a 1:10 ratio of 




Figure 2-1: SU-8 patterning for soft lithography. 
Fabrication of master molds for microfluidic devices was performed using established techniques 
for SU-8 patterning on silicon wafers.  (A) SU-8 2075 was coated on the surface of a silicon 
wafer after application to the surface by spinning the wafer at 1200 RPM.  (B) The SU-8 on the 
surface was exposed to UV light through a Mylar mask and baked on a hotplate to cure the 
polymer exposed to the light.  (C) Uncured SU-8 was washed away with solvent, leaving behind 
a positive image of the mask design on the surface of the wafer.  This positive image was then 
used to mold microfluidic devices in PDMS. 
 
the mold and hard baked for 1 hour at 120°C.  Punched ports were created in the cured PDMS 
using a sharpened 20 or 22 ga syringe needle (BD) and the punched holes were cleaned by 
passing a short length of fused silica capillary (360 µm OD, 20 µm ID, Molex) through the hole 
to clear any particulate left behind by the punch.   
Devices were cleaned with Scotch tape (3M) and bonded to 7.62 cm long (3 x 1 in) glass 
microscope slides (Corning) after exposing both the slide and the molded PDMS to oxygen 
plasma for 15 s each using a corona discharge wand (Electrotechnics).  Bonded devices were 
placed in an oven to cure at 80 °C.  Within 10 min of bonding, chips were flushed with a 
derivatization solution of trichloro(1H,1H,2H,2H-perfluorooctyl)silane (Sigma-Aldrich) 
dissolved 2% by volume in perfluorodecalin (95%, Sigma-Aldrich).  Flushed devices were baked 




2.2.2 Fluid Flow Control 
Both Syringe pumps and pressure pumps were used to drive flow in microfluidic devices.  
When using syringe pumps to drive fluid flow, Hamilton Gastight glass syringes were connected 
to Teflon (PFA) tubing using 250 µm ID PEEK unions (Valco).  30 ga Teflon tubing was 
sheathed in 1/16” outer diameter (OD), 1/32” inner diameter (ID) Teflon tubing (Cole Parmer) to 
allow the 1/16” Peek union ferrule to grip the smaller diameter tubing.  These syringes were 
driven using a Harvard Apparatus PHD syringe pump. When using gas pressure to drive fluid 
flows onto a device, sealed vials (Chemglass Lifesciences) were pressurized using an Elveflow 
OB1-Mk3 pressure pump.  Tygon tubing running from the pressure pump was connected to 
syringe needles via luer-lock connectors and these were inserted into the vial septa.  30 ga thin 
wall Teflon tubing (Cole Parmer) inserted through the same vial septa allowed fluids to exit the 
vials and flow onto the microfluidic devices when the vial headspace was pressurized. 
2.2.3 Droplet Storage, Incubation, and Re-injection 
Droplets were collected in a custom built storage chamber made from an 8 cm Pasteur 
pipette with the tapered tip removed (Figure 2-2).  Silicone or rubber stoppers (00, Fisher) were 
cut with biopsy punches (6 mm, Fisher) to cap the ends and access holes were cut to allow the 
insertion of 30 ga Teflon tubing through the caps. During chamber filling, tubing from the 
droplet generation or reagent addition device was inserted into the bottom of the chamber, 
allowing generated droplets to flow directly into the chamber.  A second segment of tubing 
inserted into the bottom of the chamber allowed excess oil to be drained off.  During chamber 
emptying, this second segment was tied off and the first was used to pump oil into the chamber.  
With no available escape through the bottom of the chamber, droplets flow out through the 





Figure 2-2: Storage, incubation, and reinjection strategy for nanoliter scale samples. 
 Storage and incubation strategy for surfactant stabilized microfluidic droplets. (A) During 
generation, droplets flow from the outlet of the droplet generator and into the bottom of the 
storage device.  The less dense aqueous droplets float to the top of the chamber, allowing excess 
oil to be drained through a drain in the bottom. (B) For extended incubation periods, droplets are 
stored in the glass chamber, but oil is circulated using a peristaltic pump. Oil flows in through 
the inlet at the top of the chamber, while an equivalent volume is removed through the outlet at 
the bottom.  (C) During droplet re-injection for both reagent addition and MADS protocols,  oil 
is pumped into the chamber through the bottom of the storage device, and droplets are pumped 
out through tubing inserted into the top.  (D) An image of 30 nL droplets stored within this 
microfluidic droplet storage device, next to a US dime for scale.  Individual droplets may be seen 
as specks of blue in the device. 
 
During extended incubation (>3 h), oil was circulated through the container by drawing oil from 
the bottom of the chamber and simultaneously pumping replacement oil in through the upper 
tubing.  Oil was circulated using a Masterflex L/S peristaltic pump (Cole Parmer). 
2.2.4 Device Imaging 
During device operation, droplet size, frequency, color, and contents were monitored 
using one of two cameras.  For high speed monitoring of droplet formation, reagent addition, and 
high frequency events, a Phantom Miro C110 high speed camera was connected to a Nikon TS2-




to the same microscope was used to monitor the droplets exiting the device to track and count 
droplets prior to sorting. 
2.2.5 Mass Spectrometer Operating Conditions 
Droplet analysis was performed using an Agilent single quadrupole mass spectrometer 
(6120B).   Droplets were directly infused from the sorting device into the mass spectrometer 
through a 360 µm OD Teflon capillary directly inserted into a commercial Agilent CE-MS 
source.
77
  Parallel sheath flow composed of deionized water was driven by a Harvard Apparatus 
PHD syringe pump and a 10 mL Hamilton gastight syringe at 30 µL/min.  Capillary voltage was 
3 kV, with 350 °C drying gas set at 30 L/min and a source pressure of 10 psi. Single ion 
monitoring was used to track the small molecules (Table S1) pyridinyl amine (m/z 123.0), ATA 
substrate amine (m/z 182.0), carnitine (m/z 162.3), neostigmine (m/z 223.0), and chlorocholine 
(m/z 122.3).  Peak height (MS dwell time) was set to 0.005s.  A sample MS trace from a 
continuous stream of droplets can be seen in Figure 2-3. 
Figure 2-3: Typical trace from direct infusion of oil-segmented droplets 
A sample trace of droplets infused onto a mass spectrometer while monitoring amine 1 (green 
trace) and  pyridinyl amine (red trace) within the droplet. As each droplet is nebulized off of the 
tip of the electrospray needle, the analytes within ionize and may be read by the mass 
spectrometer.  Droplets are interspersed with an inert oil carrying phase which does not ionize 
during electrospray.  When the spacing oil is nebulized, no signal is observed on the mass 
spectrometer.  Thus, each individual droplet appears as a peak on the two traces, with the peak 





2.2.6 Device Operation: Mass Activated Droplet Sorting 
Flow in the MADS chip is driven by a combination of syringe pumps and gas pressure.  
A 10 mL Hamilton syringe filled with perfluorinated oil respaces droplets as they enter the 
device while a 1 mL syringe drives oil into the storage chamber and droplets onto the device.  
Both syringes are driven by a single syringe pump, programed to push the 1mL syringe at 1.5 
uL/min.  Thus, the net flow onto the device is 16.5 µL/min, Droplets entering the device are 
spaced with oil at a 1:10 ratio. 
 Due to the differences in back pressure between the MS and sorting exits of the device, 
the sorting outlet vials and the sorting region are held at elevated pressure.    To do this, a 
pressurized vial drives oil into an inlet in the device located at the end of the delay line but prior 
to the sorting junction (Figure 2-4).  The sorting bifurcation flows into two vials that are 
pressurized equally using a T-split line from the gas pressure pump.  The difference in pressure 
between the oil vial and the collection vials dictates the velocity of droplet flow through the 
sorting region, and may be used to accelerate droplets as they enter the sorting region.  Typically, 
this pressure drop is held at 0.2 psi (1.4 kPa). 
The applied pressures at the sorting region of the device must be slowly ramped as the 
device begins to operate and the two exit paths are filled with droplets.  This ensures that both 
the on-chip delay line and the connected capillary maintain approximately equal back pressures 
as they fill with samples.  Once both exits are filled and flowing at the same rate, the applied 
back pressure can be maintained indefinitely and the device will operate with minimal user input 





Figure 2-4: Full schematic and detail of the MADS device 
(A) ~25 nL droplets are stored in bulk prior to being pumped onto the device.  (B) As they enter 
the microfluidic device, (C) droplets are split into two daughter droplets.  (D) The larger of the 
two halves leaves the device via an inserted Teflon capillary while (E) the smaller of the two 
remains on chip and is pumped into an extended delay line.  After the larger droplet is sprayed, a 
1.5 kV alternating current (AC) pulse at the sorting junction (F, G) directs droplets into one of 
two outlets.  A constant flow rate through the sorting region is maintained by keeping a constant 
pressure difference between a source vial of oil connected to the pressurized oil inlet and the 
outlets of the device.  Scale bar in (A) is 1 cm, all others are 500 µm. 
 
transfer capillary to be 1.2-1.6 psi (8.3-11 kPa) at the oil inlet, but this will vary depending on the 




2.2.7 DEP Sorting and Imaging Analysis 
In simple sorting experiments of analyte in water, peak threshold voltages for sorting 
were set based off of the experimentally observed peak intensities from the first few droplets.   If 
a sprayed droplet was determined to meet the sorting criteria, a high voltage alternating current 
(AC) pulse applied to the upper salt water electrode in the sorting region would pull it into the 
positive outlet; otherwise the droplet would be hydrodynamically directed to waste (Figure 2-4 
F). Collected pools of droplets were imaged on a Nikon TS2-FL with a Phantom Miro C110, and 
analyzed using imageJ software to determine sorting accuracy and enrichment.  Positive “Hit” 
droplets could be confirmed via fluorescent imaging of the hit droplets, which contained flavin 
adenine dinucleotide (FAD) to set them apart from the non-fluorescent marker and blank 
droplets. Excitation wavelength for FAD imaging was 470 nm (blue light emitting diode, LED) 
and a 525 nm Nikon fluorescein isothiocyanate (FITC) filter cube was used to filter the emission. 
2.2.8 Integrated  Electronics 
Droplet signals from the electrospray of infused droplets are acquired from a four channel 
DAC card (Agilent G1960-67039) installed in the mass spectrometer. The frequency response of 
the DAC card was improved by removing the two 1 µF capacitors from the lowpass filter stage 
for each 10x channel. The 10x channels are used to provide better signal to noise performance. A 
standalone four channel programmable gain Bessel lowpass filter (Alligator USBPGF-S1/LX) is 
used to adjust signal gain and frequency response prior to acquisition. A Sigilent SDS 1104x-E 
oscilloscope was used to monitor and record signal outputs in real time. On the microscope, a 
machine vision camera with open collector logic outputs is used to visually identify droplets 




A STM32F407 ARM Cortex M4 microcontroller board (Mikroelektronika 1685) runs 
custom software to synchronize the outputs from the mass spectrometer and the machine vision 
camera. The mass spectrometer outputs are wired into four 12-bit analog to digital (ADC) inputs, 
and the open collector camera outputs are wired into two digital inputs with internal pull-ups. A 
digital output is used to control the DEP sorting voltage. This signal is buffered by a driver 
integrated circuit (Infineon IR2125), which selectively applies 5V power to a 1.5 kV AC 30 kHz 
cold cathode fluorescent lamp (CCFL) inverter board (JKL BXA-601). The outputs of the CCFL 
inverter are wired in parallel and connected through two 100k resistors in series to the sorting 
junction electrodes. 
The microcontroller runs software written in C using Eclipse and ChiBiOS RTOS 
libraries. The microcontroller board is interfaced via universal serial bus (USB) to control 
software written in Labview on the host computer (PC). 
2.3 Mass Activated Droplet Sorting - System Overview  
The destruction of sample during ESI renders impossible the direct sorting of material 
that has been analyzed by MS. This challenge was resolved by asymmetrically splitting the 
droplets
22
 and performing analysis and sorting on the two different portions.  In this approach, 
~25 nL droplets are pumped from a storage chamber (Figure 2-2) and onto the chip (Figure 2-4), 
where they are split into two daughter droplets. The larger of the two daughter droplets flows 
into PFA capillary that is mated to a single quadrupole mass spectrometer via a sheath-flow ESI-
MS source, where it is directly analyzed without the need for oil removal (Figure 2-3).
77,105
 The 
smaller of the two daughter droplets travels into an on-chip delay line to allow time for its sister 
droplet to reach the mass spectrometer. The smaller sister droplet may be deflected into the 




sorting decision made. For testing, the accuracy of the system is determined by collecting and 
imaging the sorted droplets after each experiment. 
2.3.1 Sorting Strategy 
In principle, accurate droplet sorting could be achieved either by counting the samples 
detected by MS and aligning that count to the samples at the DEP junction, or by setting a time 
delay between the signal on the MS and the DEP pulse that matches the delay between 
electrospray and sorting. In practice, neither of these strategies is sufficiently stable. The time 
delay approach is problematic because slight differences in droplet size, spacing and velocity 
will tend to result in sorting errors. A simple counting approach is problematic because a single 
miscounted event can result in a frame shift where every subsequent sample is sorted incorrectly.  
We used a modified counting approach in which “marker” droplets were randomly mixed 
with the sample droplets so that the system could proofread its counting (Figure 2-5). To match 
the droplet entering the DEP sorting junction with its corresponding mass spectrometer 
signature, a camera monitors droplets as they enter the sorting region. The camera has image 
processing capabilities that allow it to trigger a digital signal based on droplet color. The marker 
droplets contain a unique mass analyte that is monitored by the mass spectrometer and a colored 
dye that is recognized by the camera. The signal given by marker droplets is used to synchronize 
the mass spectrometer data with the sorted droplet stream.  
The microcontroller software driving the sorting decisions uses a real-time operating 
system (RTOS) that runs several processes in parallel. The first process acquires analog input 
signals from a modified digital to analog converting board installed in the mass spectrometer.  A 
peak detection algorithm identifies peaks on each input signal and records the maximum value 




Figure 2-5: Operating principle for signal alignment between on-chip imaging and MS 
(A) A camera with on-board image-recognition software capable of recognizing the difference 
between uncolored and colored droplets may be used to track droplets within the MADS system.  
The addition of a small molecule (either amine 1 or carnitine) to a droplet dyed blue with food 
dye allows a distinct signal to be read in each split droplet as it passes the mass spectrometer and 
as it passes the camera.  The alignment of these two signals (B) allows the MADS system 
accurately track droplets as they exit either side of the microfluidic device used to analyze and 
sort them. 
 
which are markers, and which will be targeted for sorting. This data is stored in a queue of 
virtual droplets. The second process simultaneously monitors the digital output from the camera, 
classifying the droplets as markers or non-markers based on the output signal. The third process 
handles communication with the host PC, allowing the user to set sorting parameters and read 
real-time sorting statistics. 
The system synchronizes the mass spectrometer and camera droplet streams by 




directed to waste. As droplets start flowing past the camera junction, the system counts the 
number of non-marker droplets between marker droplets. Once the system detects an interval at 
the camera that matches an interval of virtual droplets stored in the queue, it enters the 
synchronized state. In this state, the stored droplet information is used to make sorting decisions 
about the droplets detected at the camera. The system will continue to monitor the intervals 
between marker droplets, and if the interval between marker droplets ever differs from the 
interval in the queue by more than three samples, the system enters the non-synchronized state. It 
then attempts to re-synchronize, starting with the next interval. The system is thereby self-
correcting and capable of responding to anomalous events such as merged or split droplets that 
can cause miscounting.  A schematic of this basic decision tree is shown in Figure 2-6.  
Figure 2-6: Decision tree detailing simple threshold-based droplet sorting 
The MADS operating system under basic threshold operating mode.  Input signals are sent to the 
microcontroller controlling MADS sorting from both the camera at the sorting region and the 
mass spectrometer.  The alignment of the camera and the mass spectrometer is performed using 
marker droplets, allowing the synchronization of signals and enabling accurate sample tracking. 
Droplet “Hit” thresholding is based on a user defined threshold set at the beginning of operation, 
and hit droplets are identified from among the non-marker droplets based on signal intensity 





In most experiments we aimed for a marker frequency of about 20%, because the 
frequent re-alignment (an average of one in five droplets) provides a regular check for the system 
to ensure it continues to sort accurately. However, the frequency of these markers is flexible and 
we have observed successful sorting with as low as 7% markers. At higher marker frequencies, a 
minimum alignment interval length may be set below which the microcontroller will not attempt 
to align. This reduces the chance of alignment to duplicate intervals, which become more 
common with increased marker frequency. 
2.3.2 Sorting Accuracy 
To assess the efficacy of the MADS device and its supporting software, we generated, 
mixed, and sorted three types of ~25 nL droplets. The bulk (~70-80%) of the droplets contained 
50 µM pyridinyl amine. Approximately 10% of the droplets contained 500 µM pyridinyl amine 
(a tenfold increase in target signal) and FAD.  
 
Table 2-1: Sorting results for MADS proof of concept, with user-defined thresholding  
Sorting results from experimental runs of the mass activated droplet sorting  device.  Sorted 
droplets contained two levels of pyridinyl amine, 50 µM and 500 µM.  In these experiments, 
target droplets with 500 µM pyridinyl amine are enriched 9-10 fold higher in the final pool 





These latter droplets served as high-signal targets for sorting. Although not used to make sorting 
decisions, the FAD is both visibly yellow and fluorescent, allowing sorting accuracy to be 
evaluated and confirmed by imaging after each experiment. The final 10-20% of the samples 
contained 500 µM ATA Substrate as a marker ion and blue food dye.  These served as markers 
for sorting alignment. 
The mixed population of droplets was pumped onto a sorting device where samples were 
split and sorted based on the signal from the pyridinyl amine. The threshold for sorting was 
manually set based on the signal intensity observed for the low and high concentration of 
pyridinyl amine. Sorted droplets were collected and imaged to analyze the accuracy of the 
sorting system. Table 2-1 summarizes five representative sorting experiments, and the results of  
 
Figure 2-7: Imaged results from a representative droplet sorting run 
 (A) Brightfield and fluorescent Images of droplets before and after sorting in experiment E in 
table 2-1. Prior to sorting, approximately 11% of droplets contain the high concentration of 
pyridynl amine along with the FAD that makes them visibly yellow.  After sorting, more than 
98% of the collected droplets exhibit the color and fluorescence associated with the target 
population.  Scale bars are 500 µm. (B)   Successful sorting is also clear when viewing the 
collected negative and positive pools of droplets macroscopically.  Collected droplets are visibly 






droplet sorting in one of these experiments are shown in Figure 2-7. In all of these experiments, 
false positive rates in the collected droplets were <12%, and false negative rates were <5% . 
We hypothesize that the majority of false negatives are collected during periods in which 
the microcontroller is in the non-synchronized state, directing all samples to waste, and that the 
majority of false positives occur when the microcontroller directing the sorting operation 
becomes misaligned. The microcontroller will synchronize as soon as it recognizes a marker to 
marker interval on the camera that matches an interval stored in the queue of droplet data from 
the MS signal. If it aligns to an incorrect interval, it will sort incorrectly until it recognizes a 
subsequent marker signal that does not match the expected interval, enters the non-synchronized 
state and attempts to realign. A minimum sync interval (in this work set to 5) may be chosen to 
avoid misalignment, as longer intervals will be more infrequent, and less likely to result in a mis-
aligned interval. We observed that misalignment and non-synchronized periods were often 
preceded by false sorting events.   Additionally, MADS operation is sensitive to miscounted 
events once it is aligned and sorting accurately.  If the microcontroller counts an unexpectedly 
large or small number of droplets in a given interval during aligned operation, it will attempt to 
re-establish alignment.  A “sync error limit” may be set to modify the stringency with which 
alignment signals must match after the MADS microcontroller is synced.  In the case of this 
work, we set the sync error limit to 3 droplets, meaning that after three extra, or three too few 
droplets within an alignment interval, the microcontroller drops alignment and attempts to re-
align. 
2.4 Experimental - MADS in Complex Matrices and Reactions 
Our results in the initial investigation of sorting efficiency demonstrated that MADS was 




degree of accuracy. However, these early tests were conducted with samples containing binary 
levels of the analyte of interest. We recognized that, in a typical screening scenario, these 
samples would neither be as simple as analyte-in-water, nor would hits be as discrete (a tenfold 
difference in concentration).  
To test the feasibility of the MADS device for use in a directed evolution workflow, we 
aimed to sort a model library of droplet samples that contained in vitro expressed wildtype (WT) 
transaminase ATA117, from Arthrobacter sp. KNK168
106
 (See 2.6, Transaminase Sequence). 
This transaminase is the same enzyme starting point that was previously evolved to produce the 
sitagliptin transaminase used in the production of the pharmaceutical Januvia.
66
 The WT enzyme 
is fairly promiscuous, and can convert the non-native ATA substrate amine 1 that we used as a 
marker ion in our early experiments into ATA product ketone 2 (1-(imidazo[2,1-b]thiazol-6-yl) 
propan-2-one) when the reaction is run in the thermodynamically favored direction (Scheme 2-
1). The transformation results in a net mass shift of 1 amu, and none of the substrates or products 
of the reaction are distinguishable optically in the reaction mix without chromatography.  
2.4.1 Bulk ivTT Reactions 
Microliter scale ivTT assays were carried out to assess the activity profile of enzymes 
expressed using commercial ivTT reagents combined with the substrates and cofactors of the 
enzyme targets.  25 µL reactions were prepared by adding 100ng of purified plasmid DNA 
coding for the transaminase enzyme of interest to 25 µL reactions of ivTT  from New England 
Biolab’s (NEB) PURExpress® In Vitro Protein Synthesis Kit.  10 µL and 7.5 µL respectively of 
solutions A and B (a proprietary mix of purified components of E.Coli protein translation) were 
mixed with 1.0 µL of the RNAse inhibitor murine (40000 units/mL, NEB) and 1.0 µL of 2.5 mM 




7.5).  DNA or PCR product and reaction substrates Pyruvate and 1-(imidazo[2,1-b]thiazol-6-yl) 
propan-2-amine (dissolved in 10mM TRIS buffer, pH 7.5) were added to the desired 
concentrations and 10 mM TRIS added to bring the reactions to volume.  For time-course 
studies, this reaction mix was prepared in larger scale and 25 µL samples were removed and 
quenched by freezing. Reactions were monitored over an 24 hour time period, with samples 
taken every hour for the first 4 h, and then at 6 h, 8h, and 24 h.   
2.4.2 Plug-flow Mass Spectrometry for Assessment of Bulk ivTT Reactions 
Bulk reaction analysis was performed using plug-flow infusion onto an Agilent single 
quadrupole mass spectrometer (6120B).   Samples were directly infused into the mass 
spectrometer through a 360 µm OD, 150 µm ID Teflon capillary directly inserted into a 
commercial Agilent CE-MS source
77
.  Parallel sheath flow composed of deionized water was 
driven by a Harvard Apparatus PHD syringe pump and a 10 mL Hamilton gastight syringe at 50 
µL/min.  Capillary voltage was 3 kV, with 350 °C drying gas set at 30 L/min and a source 
pressure of 10 psi. Single ion monitoring was used to track the small molecules of interest in the 
reaction solution.  Peak height (MS dwell time) was set to 0.015s.  
Sample plugs for infusion onto the MS were generated using a 500 µL Hamilton gas tight 
syringe filled with Novec7500 oil and connected to 60 cm of 360 µm OD, 150 µm ID Teflon 
capillary.   The syringe was placed into a Harvard Apparatus syringe pump set to withdraw 
mode. The pump was set to withdraw at 50 µL/min and the Teflon capillary tubing inserted into 
a vial of oil. Once liquid began to flow into the tubing, it was serially dipped into the sample of 
interest and then the vial of oil, dwelling in each for 5-10s.  This created a series of discreet 





Figure 2-8: Schematic and micrograph of a droplet-pairing reagent addition device 
A droplet pairing reagent addition device is shown with important regions labeled. An oil inlet 
(A) and an aqueous solution inlet (B) combine aqueous sample with fluorinated oil to produce 
droplets.  These inlets are driven by a pressure pump which pressurizes vials of the respective 
liquids and drives them onto the chip through inserted tubing.  A syringe pump drives 1 nl 
droplet reinjection by pumping oil into a glass storage chamber filled with the droplets, which 
are then driven into inlet (C) at a regular flow rate. Moat electrodes (D) are filled with salt water 
and  electronically connected to ground to prevent any on-chip electric fields from merging these 
small 1 nl droplets as they run onto the Small droplets and large droplets pair up in the horizontal 
region between D2 and E1 (inset micrograph) before being merged in the high voltage electric 
field applied across channels E1 and E2 . 
 
2.4.3 Device Operation: Reagent Addition 
Reagent addition is used to produce sample droplets with complex contents by mixing 
two different droplets together on a microfluidic device.  We used this technique to express 
transaminase DNA in vitro within microfluidic droplets by adding 1 nL droplets of transaminase 
DNA to droplets of ivTT. This was performed on a droplet pairing device (Figure 2-8) and was 
driven using a combination of gas pressure and syringe pumps to drive fluid flow. To ensure 1 
nL droplets flowed on to the device at a steady rate, a 500 µL Hamilton gastight syringe was 
used to flow perfluorinated oil at 0.5-1.0 µL/min into the bottom of the droplet storage chamber, 




used to pressurize two vials to 2 psi (13.8 kPa).  One vial was used to hold the perfluorinated 
carrier phase for droplet generation while the other holds the aqueous sample used for droplet 
generation.  The pressure on the vial of aqueous material was adjusted to create droplets of a pre-
determined (30 nL) size at the flow focusing region of the device, while the syringe pump flow 
rate was adjusted to match the frequency of 1 nL droplet introduction to the frequency of droplet 
generation.  Paired droplets flow downstream past two salt water
107
 channels where an applied 
1.5 kV AC field merges the two droplets.  Exiting droplets flow directly into a second droplet 
storage chamber.  This allowed droplets to be transferred from device to device without ever 
necessitating the use of a pipette which could shear large 30 nL samples. 
2.4.4 ivTT Reaction Conditions for Signal Calibration 
To make each dilution of ATA substrate amine in ivTT for calibration experiments, 250 
µL of cell free expression buffer was created from 100 µL and 75 µL respectively of solutions A 
and B (a proprietary mix of purified components of E.Coli protein translation), 10 µL of the 
RNAse inhibitor murine (40000 units/mL, NEB), 10 µL of 2.5 mM Pyridoxal phosphate (PLP) 
in 10 mM TRIS (pH 7.5), and 1-(imidazo[2,1-b]thiazol-6-yl) propan-2-amine in nuclease free 
water such that seven final samples were created at 5 mM, 1 mM, 500 µM, 250 µM, 100 µM, 50 
µM, and 0 µM.  Every other solution received 1µlof McCormick blue food dye to aid with 
visualization.  
2.4.5 ivTT Reaction Conditions for Reagent Addition 
To make the stock solutions of ivTT to which DNA was added in our enzyme assays, 1 
mL of cell free expression buffer was created from 400 µL and 300 µL respectively of solutions 
A and B, 40 µL of RNAse inhibitor, 40 µL of 2.5 mM PLP in 10 mM TRIS , 20 µL of nuclease 




pyruvic acid in 10 mM TRIS (pH 7.5).  Final samples contained 1 mM amine 1, 100 µM PLP 
cofactor, and 1 mM pyruvate.    An identical 250 µL solution of expression buffer was created 
for the marker droplets with the addition of 2.5 µL blue McCormick food dye and 2.5 µL of 50 
mM L-carnitine in water to the 50 µL 5 mM amine 1 and pyruvic acid added.   
1 nL droplets containing DNA (50 ng/µL final), FAD (5 mM final) and neostigmine (25 mM 
final) in water were formed using a commercial flow-focusing device (BioRad DG8). Upon 
addition to droplets of ivTT, these droplets express transaminase and are both visibly yellow and 
fluorescent.  These small DNA droplets were pooled and mixed with blank water droplets and 
droplets containing 50 ng/µL WT plasmid and 50 mM chlorocholine.  ivTT droplets that 
received these secondary DNA-containing droplets show activity, but not fluorescence and were 
used as a positive control signal for thresholding.   
The combined pool of mixed 1 nL droplets contained all three varieties of droplet at a 
1:1:6 ratio with the blanks making up the bulk.  This mixed emulsion was reinjected into a 
reagent addition device that segmented ivTT solution into ~30 nL volumes before pairing these 
larger volumes with a small droplet and merging them in a 1.5 kV AC electric field (Figure 2-8)  
2.5 Reading Enzyme Activity in ivTT Reaction Mix 
In order to verify that we could observe the enzyme activity assay in droplets, the ivTT 
reaction was first performed in bulk and analyzed in microfluidic plug-flow format on the mass 
spectrometer.  100 ng/µl DNA was added to ivTT reaction mix at a 25:1 volume ratio and kept at 
room temperature on the benchtop.  The reaction was quenched by freezing 20ul samples at 
regular time intervals. Droplet plugs were then formed from these samples in capillary using a 
syringe pump in withdraw mode as described in 2.4.2.
22,59
 Both the substrate and the product of 




Figure 2-9:One-pot  ivTT expression of transaminase analyzed in bulk and droplets 
(A) in-vitro expression of the transaminase enzyme was performed by adding DNA to ivTT 
solution along with amine substrate for the transamination.  This reaction was sampled 
periodically to determine if enzyme expression could be observed as a drop in the amine 
concentration and a corresponding rise in the formation of the ketone product.  Plug-flow 
analysis of the transaminase reaction performed in bulk shows that the amine 1 signal decreases 
as the ketone 2 signal rises, demonstrating that the transamination occurs as DNA is expressed 
within the reaction. (B) When the fully reacted (24 h after DNA addition) and the unreacted bulk 
ivTT was then segmented into 30 nL droplets and infused using the MADS device to read 
samples, both the decrease in the amine signal and the increase in the ketone signal within 30 nl 
samples could still be observed. However, in this format it is evident that the ketone product is 





substrate concentration begins to decrease noticeably in the first few hours, and that it continues 
to drop over the course of a full day (Figure 2-9). 
Following this confirmation, 30 nL droplets were produced from the bulk reaction mixes.  
The negative control reaction mixture that received no DNA and the reaction mixture that 
incubated for 24 h were compared by infusing these droplet samples onto the MADS device and 
reading the infused 30 nL droplets.  Figure 2-9 B shows the ion traces observed by monitoring 
first amine 1 and then ketone 2 during the transition between the two samples.  In this 
experiment, the transition between active and inactive enzyme samples is distinct when 
monitoring the amine substrate, but when monitoring the ketone product, the change appeared 
more gradual.  This suggested that ketone 2 was moving between samples.  This type of 
molecular transfer has been reported previously, 
94,95,108-110
 and we were concerned that this 
would ultimately make active and inactive samples difficult to distinguish. Given this data, we 
elected to monitor reaction progress by observing the reduction of the ATA substrate (amine 1), 
rather than the increase in the ketone 2 product. 
2.5.1 MS Dynamic Range in Biological Matrix 
To assess the ability of droplet MS to quantitatively distinguish between varied 
concentrations of amine 1 in complex ivTT matrices, droplets were made from ivTT doped with 
amine 1 at concentrations from 50 µM to 5 mM.  These bulk solutions were then segmented into 
30 nL droplets and collected in layers in the same storage chamber. The droplet samples were 
pumped onto the MADS device one concentration at a time by drawing the chamber outlet 
tubing through each layer of stored droplets (Figure 2-10). Signal intensities for each sprayed 
concentration show clear step-change transitions between each layer of stored samples, with 




Figure 2-10: Concentration dependent signal intensity for droplets of ivTT with amine 1 
 (A) Six concentrations of amine 1 in droplets of ivTT are sprayed sequentially.  Clear step 
changes are visible as each population is sprayed and (B) the averaged extracted ion count (EIC) 
from 225 peaks in each population show a linear response  in signal with increasing substrate. 
Error bars show standard error of the mean peak height, which at these scales are all smaller than 
marker size.  (C) The six populations of droplets are all clearly distinct and baseline resolved 
when unmixed, with none showing significantly wider spread relative to the log of signal 
intensity. 
 
concentration, and plotted, showing a linear response to amine 1 concentration with a limit of 
detection of 30 µM. The logarithmic transformation of all extracted peak values was then taken, 
and the frequency distribution of each signal intensity range plotted, revealing clear clusters of 
sample intensities corresponding to the 6 sample concentrations. 
To demonstrate the capability of the MS to distinguish between these droplets in a 




Figure 2-11: Demonstration of accurate assessment of mixed droplet concentrations 
 (A) A mixed population of droplets containing 6 concentrations of amine 1 in ivTT are sprayed 
after an hour of incubation. (B) Extracted peak heights from this mixture of droplets reveals the 6 
component populations within the mixture. These histograms of droplet intensity appear less 
resolved from one another than their unmixed counterparts in Figure 2-11, likely due to some 
low-level transfer of amine 1 between droplets with higher and lower concentration.  
  
binned ion intensity for the mixed droplets are shown in Figure 2-11. The histogram of droplet 
signal intensities shows resolution of each of the six underlying concentrations of ATA Substrate 
amine in the droplets. These histograms exhibit some drift towards the center when compared to 
those generated from the sequential spray experiment, possibly due to a small degree of substrate 
transfer between droplets.  Nevertheless, this data may be used to calculate the Z’ factor for a 
potential screen of samples starting at 1 mM and running to 95% conversion (50 µM), giving a 




concentrations in droplets containing complex, practical sample, and the potential to sort these 
populations based on MS signal. 
2.5.2 Droplet MS Drift in Dynamic Reaction Screening 
Signal drift can affect sorting accuracy if a fixed MS signal threshold is used as the 
sorting criteria. In our early experiments with DNA bearing ivTT droplets, we observed two 
forms of MS signal drift.  First, enzymatic activity in droplets is not quenched at the initiation of 
analysis. Figure 2-9 illustrates the change over 24 h in substrate and product in a bulk reaction of 
expression and enzymatic turnover. The same occurs in droplets and can be seen as an increasing 
difference in target signal between inactive and active droplet signals over several hours of a 
screen (Figure 2-12).  
Figure 2-12: Demonstration of complete in-droplet expression and activity of ATA117 
A 3 h trace of amine 1 signal in droplets expressing transaminase.  A gradual increase in the 
separation between inactive (black circles) and active droplets containing DNA (blue and yellow 
circles) demonstrates the effect of an unquenched enzyme reaction in droplets. In this plot, active 
samples are divided into two populations: positive control (yellow circles) and model library 
(blue circles). The positive control signal can be averaged by the adaptive sorting algorithm 






Second, we also observed a more gradual drift in the maximum MS intensity of the ATA 
Substrate in our system, which declined by 15-20% over 6 h.  Significantly, the signal for the 
marker ions remained stable during this same period, suggesting that the signal loss was specific 
to the ATA Substrate. We theorized that it stemmed from the slow transfer of ATA Substrate 
from the inactive droplets in the system to those expressing active protein. These two 
mechanisms for change in signal over time indicate the need to account for this signal drift 
during long analysis.   
 
Figure 2-13: Decision tree detailing activity-based thresholding in droplet sorting 
The MADS operating system under adaptive thresholding mode.  Input signals are sent to the 
microcontroller controlling MADS sorting from both the camera at the sorting region and the 
mass spectrometer.  The use of three separate MS channels for droplet identification allows for 
the categorization of droplets as alignment markers, library samples, and positive control 
samples.  The alignment of the camera and the mass spectrometer is performed using marker 
droplets, allowing the synchronization of signals and enabling accurate sample tracking. Droplet 
“Hit” thresholding is based on the average signal from positive control samples rather than a user 
defined threshold set at the beginning of operation, and is only applied to the sorting of droplets 
categorized as sample droplets.  This enables the system to adapt to changing concentrations of 





To maintain accuracy over time, we developed an “adaptive thresholding” technique to 
change the threshold for selection as signal drift occurred (Figure 2-13). In this modified 
algorithm, hits are defined in comparison to the running average (16 samples) of a set of positive 
control signals mixed into the screened population. These positive control samples can be 
marked with a unique ion that distinguishes them from the sample population, allowing the 
algorithm to avoid sorting them as hits. We used the small molecules chlorocholine and 
neostigmine to mark the positive control samples and the model library samples respectively; 
these quaternary amines are robustly contained within droplets and readily ionize under ESI 
conditions. 
In the adaptive mode of operation, the program will only attempt to collect samples 
marked by the presence of neostigmine. The threshold defaults to the average signal of the 
samples containing chlorocholine (Figure 2-12, orange line), but may be adjusted to be more or 
less stringent using a multiplier, termed the “sorting ratio”. Increasing the sorting ratio raises the 
threshold for a hit above the average positive signal, and allows a larger portion of the model 
library to be targeted. 
2.6 Proof of Concept: Enzyme Screening  
To demonstrate MADS on enzyme samples expressed in droplets, we created and 
screened a model library of transaminase enzymes by in vitro expression. For this experiment, 
three types of sample droplet were formed through the electrocoalescence of 1 nL droplets to ~25 
nL droplets of ivTT reaction mix and ATA Substrate.
111
 When the added 1 nL droplet contained 
WT DNA, neostigmine, and FAD, a visibly yellow, fluorescent droplet expressing transaminase 
was produced. These model library samples were targeted for sorting, and the added FAD made 




addition contained WT DNA and chlorocholine, an active positive control droplet was produced. 
1 nL water droplets made up the bulk of the small droplets, and the addition of these produced 
inactive ivTT samples. Marker droplets for synchronization were generated from ivTT doped 
with carnitine and blue food dye and were mixed into the final pool of droplet samples.  
The microcontroller utilized the running average of the amine 1 substrate signal in 
positive control droplets containing chlorocholine to adjust the sorting threshold. The 
neostigmine channel was used to identify model library members that would be considered for 
sorting.  The carnitine channel was used to identify marker droplets. 
Because all model library droplets were expressing the same WT DNA as the positive 
control droplets, the default threshold produced by the average wildtype signal only targeted 
approximately 50% of the active droplets.  The sorting ratio was therefore set above 1 in 
experiments that aimed to recapture all of the model library droplets from the mixed pool. 
Droplets that showed amine 1 signal below this threshold were targeted for sorting, and those 
that did not were rejected and allowed to flow to waste. In a screening scenario, this cutoff will 
likely be set to more stringent values to select only for high performance hits.  
After 3-4 h incubation to give the enzyme time to react, the droplets were reinjected and 
sorted, with samples taken and imaged at 1 or 2 h intervals. A representative trace of the mass 
signal for the droplets is shown in Figure 2-14.  Model library droplets show a reduction in ATA 
Substrate, a high neostigmine signal, and are fluorescent. Positive control droplets show a similar 
reduction in ATA Substrate but display high chlorocholine signal, and are therefore not targeted 
for sorting. Marker droplets and droplets that did not receive an addition containing DNA remain 





Figure 2-14: Representative signal trace for activity based thresholding in MADS 
A mixture of 1 nL droplets that occasionally contained plasmid DNA with MS traceable analytes 
are added to 30 nL droplets to create a mixed pool of large droplets where some express active 
protein . The droplets are sprayed, and the small molecule tracers neostigmine and chlorocholine 
allow the MADS microcontroller to identify those that have received and expressed this DNA. A 
modified sorting algorithm reads the resultant trace and uses the average amine signal from the 
droplets containing chlorocholine (purple trace) to set the sorting threshold for those containing 
neostigmine (green trace). Average signals for the positive control, shown as Avg.(+), and 
average signals from negative samples, shown as Avg.(−), are marked to highlight how all 
droplets containing these two marker signals exhibit the expected drop in Amine signal.  
 
In all experiments with a sorting ratio above 1.3, the collected droplet pools showed 
enrichment above 90%, from a starting occupancy of approximately 10%. Collected droplets 
were imaged and analyzed, and Table 2-2  shows the results from 5 experiments with a sorting 




Table 2-2: Sorting results for MADS proof of concept, with activity-based thresholding 
Sorting results from experimental runs of the mass activated droplet sorting  device after ivTT 
expression of DNA in droplets.  Sorted droplets contained either no DNA and therefore no active 
enzyme to consume the loaded amine 1, or DNA and ivTT expressed active enzyme.  Half of 
those containing DNA received chlorocholine with DNA during reagent addition, while half 
received neostigmine and FAD.  Those containing neostigmine were sorted based on the average 
signal of those containing chlorocholine.  Target droplets are enriched 8-9 fold higher in the final 
pool relative to the starting pool. 
 
droplets dosed with DNA, FAD and Neostigmine were targeted for sorting. Collected droplets 
were imaged after sorting, and confirmed as winners using the fluorescence of the FAD to 
evaluate accurate sorting (Figure 2-15). Accuracy was found to be on par with our previous 
experiments using aqueous solutions of known analyte concentration.  
The results of this experiment show the capability of the system to perform multiplex 
analysis in a complex reaction mixture and use information from an ongoing chemical reaction to 









Figure 2-15: Droplet expression and sorting results  
(A) Brightfield and fluorescent Images of droplets before and after sorting in a representative 
experiment from table 2-2. Droplets expressing transaminase DNA (yellow) are sorted based on 
the presence of active enzyme using the adaptive thresholding technique.  These are highlighted 
with red arrows prior to sorting. False positives and negatives in the collected pools are 
highlighted with yellow arrows in the images of droplets after sorting. Scale bars are 500 µm.  
 
2.7 Conclusions 
Although FADS has been the most utilized approach for sorting droplet samples since its 
introduction
73
 and has enabled sorting at throughputs unachievable in conventional systems, 
indirect assays often lead to off-target selection. 
92
 A screen that directly interrogates the analyte 
of interest is far preferable.  With careful assay development, both FADS and AADS have been 
used to screen industrially relevant enzymes, 
32,93
 but the vast majority of potential targets will 
not be amenable to such reporter assays. 
Here, we have demonstrated an adaptive, self-correcting MADS system with the ability 




microfluidics workflows and significantly broadens the applicability of these miniaturized 
systems. 
The inherent label free nature of MS makes MADS a valuable tool for probing 
chemistries that cannot be easily adapted to FADS, broadening detection to include most 
molecules that are readily ionizable with ESI. While it does not achieve the full information 
density of HPLC-MS analysis, the resolution of direct MS allows numerous analytes to be 
simultaneously monitored, creating the potential for selective, multifaceted probes of activity. 
For screening chemical reactions, the ability to detect changes in mass is more broadly 
applicable than changes in spectra. Although MADS sorting rates are 1000-fold slower than 
those demonstrated with FADS, they are still 100-fold faster than industry standard HPLC-MS 
methods. The higher detection limits of MADS as demonstrated are on par with absorbance 
screens.  This should be sufficient for most applications, but could be improved by adapting the 
method to a triple quadrupole mass spectrometer if desired.  
 




























































Chapter 3: Chapter 3 Integrated Nanoliter Sample Processing and Mass Spectrometry for the 
Expression and Selection of a Transaminase Library 
3.1 Introduction  
Enzyme-mediated catalysis is a powerful tool in the arsenal of modern synthetic 
chemistry.  The enhanced selectivity, efficiency, and safety of biocatalytic transformations make 
enzyme catalysis an attractive alternative to transition metal-based synthetic 
methods.
64,66,67,69,70,112
   The application of chemoenzymatic and multi-enzymatic processes in 
pharmaceutical synthesis has driven both the rapid preparation of lead compound libraries and 
the sustainable production of active pharmaceutical ingredients.
66
  For example, Merck’s design 
of an innovative biocatalytic cascade for the manufacture of islatravir
69
 highlights the industrial 
utility of enzymes as robust catalysts for accelerating pharmaceutical syntheses, and the potential 
to use re-purposed enzyme cascades to affect complex, multi-step transformations on non-native 
chemical substrates. However, in order to optimize enzymes for enabling this stepwise 
transformation of a novel substrate, intensive engineering and screening programs must be 
undertaken to identify biocatalysts with optimized activity on non-native building blocks for 
each step along the way.  In this process of directed evolution, tens of thousands of unique 
enzymes must be expressed and assayed to select the top candidates with the desired properties. 
In the search for novel active enzymes for biocatalytic applications, the use of robust, 
high-throughput screening and detection methods is of paramount importance.
71,92,113
  Current 
strategies rely on a combination of chromatographic separation and mass spectrometry or UV 
detection, processes that possess analytical throughputs of several minutes per sample.  Assay 
development and setup also contribute to limited throughputs; library preparation, cell growth, 
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protein induction, cell lysis, and chemical assays must all be carried out stepwise in well plate 
format.  With evolution programs screening thousands of enzymes per round, current directed 
evolution methods that are assessed chromatographically necessitate weeks of screening work 
per round, which translates to a timescale of months to years needed to develop a robust enzyme 
catalyst.   
Since sample production and screening present critical bottlenecks to protein engineering 
efforts, the development of rapid analytical strategies and sample processing workflows is of 
utmost import. Flow cytometry
5
 and microfluidic droplet sorting 
systems
29,32,34,37,38,40,73,75,89,114,115
have enabled rapid assessment of enzyme libraries reaching 10
6
 
members, but have relied almost exclusively on photometric detection and fluorescent labeling, 
which are often challenging to implement in small molecule transformations. Systems that 
combine nanoliter droplet sampling with direct mass spectrometry have been explored as label 
free analytical methods to both reduce sample consumption and improve throughput for protein 
engineering, synthetic method development, and drug discovery workflows.
47,77,100,101,116
  We 
have recently demonstrated the coupling of droplet microfluidics with electrospray MS for the 
label-free assessment of up to 2,500 nanoliter samples per hour using mass activated droplet 
sorting (MADS) .
80
   
3.1.1 Transaminases as Biocatalytic Targets  
In the previous chapter, nanoliter droplet mass spectrometry and microfluidic droplet 
sorting were combined to demonstrate mass activated droplet sorting (MADS) of 30 nL 
microfluidic droplets.  in vitro expression of a transaminase enzyme was performed within 30 nL 
droplets using a reagent addition device, and assessed these samples with the MADS platform to 
demonstrate its analytical and microfluidic sorting capabilities with a biological reaction in a 
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droplet.  Transaminase enzymes are valuable biosynthetic tools for the production of 
enantiomerically pure chiral amines that are often used as intermediates in the synthesis of 
complex, pharmaceutically important organic molecules.
117
 Transaminases catalyze the exchange 
of an amine and a ketone functional group between two molecules with these moieties, a 
catalytic process that enables cells to form amino acids from the corresponding keto-acid in vivo. 
Transaminases that accept aliphatic ketones and amines as their substrates are attractive targets 
for directed evolution efforts.
118
   
Most transaminases perform the synthesis of enantiomerically pure amines through the 
use of the coenzyme pyridoxal-5’-phosphate (PLP).  In the transaminase active site, PLP readily 
forms a Schiff base with amines, which allows it to be covalently bound to lysine in the active 
site of transaminase enzymes (Figure 3-1). Nucleophilic addition of the amine substrate onto this 
PLP-bound imine displaces the lysine and forms an imine intermediate with the substrate amine, 
which then undergoes proton rearrangement and hydrolysis to release the ketone product, leaving 
the enzyme-associated PLP aminated as pyridoxamine phosphate (PMP).  In the second half of 
this “ping pong” reaction, the PLP cofactor is regenerated from PMP.  Here, a ketone donor 
undergoes attack by PMP and subsequent amination to generate and release an amine.  
Enantiospecificity in this reaction stems from favored coordination of one enantiomer over the 
other during the protonation of the imine by the catalytic lysine in the active site. 
  Transaminases have seen notable adaptation to industrial processes and the development 
of higher throughput methods for their evolution is of particular interest.   In this work we aimed 
to further utilize microfluidic droplet mass spectrometry and establish a workflow that would (i) 




Figure 3-1: Mechanism for the ATA117-mediated transformation of an amine  
Enzyme mechanism for the transformation of non-native substrate 1 into product  2 by the 
wildtype transaminase ATA117.  This ping-pong two substrate reaction is catalyzed by the 
cofactor PLP and simultaneously converts pyruvate to alanine.  Here it is shown using 1-
(imidazo[2,1-b]thiazol-6-yl) propan-2-amine propan-2-amine, or the “ATA Substrate” pictured 
here as the amine donor in the transformation of Pyruvate to Alanine. 
 
different mutations on a parent transaminase enzyme expressed in individual microdroplets, (ii) 
analyze the relative activity of the expressed enzymes using droplet MS, and (iii) accurately 
recover and identify potential catalysts that outperformed the parent enzyme from which they 
were derived and to which they were compared.  
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3.2 Experimental Methods 
Protein engineering and directed evolution is carried out in a stepwise process in which a 
library of enzymes is expressed, isolated, and assayed to determine the individual activity of each 
library member.  The best variants are then sequenced, enabling the identification of specific 
mutations that improve the catalytic efficiency, selectivity, and specificity of the enzyme target.  
These mutations may then be combined or further iterated upon to drive the enzyme target 
towards the ideal enzyme for the transformation at hand.  In order to express and screen a library 
of enzymes in microdroplets, we developed a microfluidics based workflow to perform each of 
the core steps of the protein engineering and directed evolution screening workflows within 
microdroplets.  
3.2.1 Bulk ivTT Reactions 
Microliter scale in vitro transcription and translation assays were carried out to assess the 
activity of enzymes expressed using commercial ivTT reagents combined with the substrates and 
cofactors of the enzyme targets.  25 µL reactions were prepared by adding 100 ng of purified 
linear DNA coding for the enzyme of interest to 25 µL reactions of ivTT  from New England 
Biolab’s PURExpress® In Vitro Protein Synthesis Kit.  10 µL and 7.5 µL respectively of 
solutions A and B (a proprietary mix of purified components of E.Coli protein translation) were 
mixed with 1.0 µL of the RNAse inhibitor murine (40000 units/mL, NEB) and 1.0 µL of 2.5 mM 
Pyridoxal phosphate in 10 mM TRIS (pH 7.5).  DNA or PCR product and reaction substrates 
Pyruvate and 1-(imidazo[2,1-b]thiazol-6-yl) propan-2-amine (dissolved in 10mM TRIS buffer, 
pH 7.5) were added to the desired concentrations and 10 mM TRIS added to bring the reactions 
to volume.  For time-course studies, this reaction mix was prepared in larger scale and 25 µL 
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samples were removed and quenched by the addition of 1 µL of 10% formic acid. Reactions 
were monitored over an 8 hour time period, with samples taken every hour.   
3.2.2 Plug-flow Mass Spectrometry for Assessment of Bulk ivTT Reactions 
Bulk reaction analysis was performed using plug-flow infusion onto an Agilent single 
quadrupole mass spectrometer (6120B).   Samples were directly infused into the mass 
spectrometer through a 360 µm OD, 150 µm ID Teflon capillary directly inserted into a 
commercial Agilent CE-MS source
77
.  Parallel sheath flow composed of deionized water was 
driven by a Harvard Apparatus PHD syringe pump and a 10 mL Hamilton gastight syringe at 50 
µL/min.  Capillary voltage was 3 kV, with 350 °C drying gas set at 30 L/min and a source 
pressure of 10 psi. Single ion monitoring was used to track the small molecules of interest in the 
reaction solution.  Peak height (MS dwell time) was set to 0.015s.  
Sample plugs for infusion onto the MS were generated using a 500 µL Hamilton gas tight 
syringe filled with Novec7500 oil and connected to 60 cm of 360 µm OD, 150 µm ID Teflon 
capillary.   The syringe was placed into a Harvard Apparatus syringe pump set to withdraw 
mode. The pump was set to withdraw at 50 µL/min and the Teflon capillary tubing inserted into 
a vial of oil. Once liquid began to flow into the tubing, it was serially dipped into the sample of 
interest and then the vial of oil, dwelling in each for 5-10s.  This created a series of discreet 
sample plugs, which were then infused at 50 µL/min into the MS for analysis. 
3.2.3 PCR Amplification of Transaminase DNA 
 DNA sequences were amplified from template plasmid or linear DNA using New 
England Biolab’s Q5® High-Fidelity 2X Master Mix. Each 20 µL PCR reaction was created 
with 10 µL of master mix (containing polymerase, dNTPs, and the necessary buffer components 
for PCR), forward and reverse primers (100 nM final concentration in the reaction), and DNA  
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Table 3-1: PCR Protocols  
PCR recipes used for the amplification, assembly, and sequencing of DNA in the MADS 
directed evolution workflow.  
 
template (ranging in concentration from 1 pg/µL to 1 ng/µL in the final volume). These reactions 
were amplified according to the protocol “Q5_Bulk” in Table 3-1.   PCR Product was purified 
using ZYMO Research DNA Clean and Concentrator (DCC) columns, according to the 




3.2.4 Single Site Mutation (SSM) Library Creation 
pUC57 vector containing the wildtype transaminase and a gene for kanamycin resistance 
were provided by our collaborators at Merck.  In order to create a library of single site enzyme 
variants, primers with NNK mutations (coding for every available amino acid) at each amino 
acid position for the wildtype transaminase were designed using Mutation Maker software and 
ordered from Integrated DNA Technologies.  These mutations were distributed into three primer 
libraries consisting of positions at the core of the protein (Figure 3-2), highly accessible surface 
residues (tier 2), and remaining surface residues (tier 3).    Tier 1, consisting of 96 selected 
mutations, was used for all experiments described in this work (Table 3-2).   
For SSM fragment generation, 500 nM forward and reverse primers coding for a single 
site mutation are paired with 500 nM reverse and forward primers (respectively, in two separate  
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Figure 3-2: Structure of the ATA117 dimer  
Structure of the ATA117 dimer with PLP and amine 1 bound, and the core amino acids targeted 
by the Tier 1 SSM library highlighted with red spheres.  96 sites within the core of the protein 
were targeted for mutagenesis 
 
 




reactions) bracketing the gene of interest in a 20 µL PCR reaction containing 10 µL of NEB Q5 
2x master mix and 5 ng of template plasmid.  PCR amplification (Following protocol Q5_SSM, 
Table 3-1) in the presence of template plasmid generates fragments running in opposite 
directions from the mutation site to the end of the genes of interests. Primers NEST_FW and 
NEST_RV (Table 3-3) were used to generate forward and reverse fragments of the gene of 
interest, including the T7 promoted ribosome binding domain and the T7 terminator bracketing 
the gene.  2.5 µL of both the forward and the reverse fragment product were combined, and these 
fragment mixtures were then treated with 2µL of ExoSAP-IT (thermoFisher) and 0.5 µL of Dpn1 
(Promega) and incubated at 37 degrees for an hour to remove remaining plasmid template after 
the PCR reaction.  7.5µL reactions were diluted 20-fold in ultrapure water after treatment. 
After fragment treatment and dilution, 5 µL of fragment mix was added to 12.5 µL of Q5  




master mix, along with 1.25 µl of forward and reverse NEST primers at 10 mM, with final 
reaction volume brought to 25 µL.  Splicing by overhang extension (SOE) PCR was performed 
by amplifying these mixtures using the SOE_PCR protocol (Table 3-1).  10 µL of each SOE 
PCR reaction was pooled to give a mixture of all library members in a single solution, and the 
mixture was run on a 1% agarose gel for fragment isolation.  The band corresponding to the gene 
of interest (GOI) was cut from the gel and purified using a ZYMO Research gel extraction and 
purification kit and quantified using a nanodrop spectrophotometer.   
Purified linear sequences were assembled into pUC57 backbone via Gibson assembly
119
 
prior to transformation into NEB 10β E. coli cells (See 2.8 Supplemental Information). Linear 
vector backbone was generated in 20 µL Q5 PCR reactions from the template plasmid (5 ng/rxn) 
using primers NEST_FW_RV and NEST_RV_FW (0.1 mM final) and PCR protocol Q5_BB.  
PCR Product was treated with the addition of 2 µL of Dpn1 and incubated at 37°c for 1hr and 
then purified using a ZYMO DCC kit, and quantified on a nanodrop.  50 ng of pUC57 backbone 
and 50 ng of library fragment were combined with 5 µL of NEBuilder® Hifi DNA assembly 
master mix in a 10 µL reaction and incubated at 50°c for 15 min.  Reactions were diluted 3-fold 
and 1 µL was then directly added to 50 µL of NEB 10β electrocompetent cells and 
electroporated using a Bio-Rad MicroPulser. 
After transformation and plating, single cell colonies were picked for library sequence 
confirmation and high-density plated cells were scraped from plates to miniprep plasmid stock 
solutions.  Plasmid miniprep was carried out using ZYMO Research’s plasmid miniprep kit.  
Library fragments for digital PCR were generated using 20 µL PCR reactions containing 10 µL 
Q5 2x master mix, 100 nM NEST_FW and NEST_RV, and 1 ng of plasmid, amplified using the 
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Q5_Bulk protocol.  Reaction product was purified on a ZYMO DCC column and eluted in 
nuclease free water. 
3.2.5 Digital PCR and Droplet DNA Dilutions 
Purified DNA was diluted serially in nuclease free water at concentrations ranging from 1 
ng/µL to 1 fg/µL.  20uL PCR reactions were created using 25 µL of BioRad Supermix for probes 
(No dUTP), 75 µL of NEB Q5®  HiFi PCR 2x Master mix,  76 µL of SYBR Green [invitrogen, 
10,000x in DMSO] diluted 2000 fold in nuclease free water (5x final concentration), 2uL each of 
forward and reverse primers (10 µM), 10 µL of 50 mM Neostigmine or 200 mM chlorocholine 
in nuclease free water, and 10 µL of diluted DNA.  20 µL PCR mix samples were segmented 
into droplets in Novec 7500 fluorinated oil (3M) with 2% (w/w) surfactant (008, RAN 
biotechnologies) using a commercial droplet generator system (BioRad QX200).    Droplets were 
thermocycled using the protocol “Q5_Droplet” in Table 3-1, and the resultant emulsion imaged 
on a Nikon TS2 fluorescent microscope under 470 nm LED excitation and 534/55 nm filtering to 
determine droplet occupancy.   
Based on a rough molecular weight of 1100 kDa and a droplet volume of 1.0 nL, a stock 
DNA concentration of 72 fg/µl should give an average of 1 DNA molecule per droplet.  
Distribution of DNA in droplets will follow a Poisson distribution with λ=1, and at this 
concentration, 59.3% of droplets will be empty, 31.0% will contain 1 strand of DNA, 8.1% will 
contain 2 strands and the remainder will contain 3 or more.  Typical running dilutions for DNA 
added to digital PCR reactions ranged from 10 fg/µl to 100 fg/µl depending on the template 
material molecular weight, purity and concentration read on the Nanodrop
TM 
spectrophotometer 
(Thermo Scientific), and fresh dilution series were performed each time digital PCR was 
performed.  DNA dilution series were made from frozen stocks diluted to 1 ng/µL. 
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3.2.6 PCR Droplet Fluorescence Activated Droplet Sorting  
After digital PCR amplification, PCR droplets were transferred with a pipette into a 
custom built storage chamber made from an 8-12 cm long segment of NMR tube.  Silicone 
stoppers (00, Fisher) were cut with biopsy punches (4 mm, Fisher) to cap the ends and access 
holes were cut with 22 ga needles to allow the insertion of 30 ga Teflon tubing through the caps 
(See Figure 2-2).  
Droplets were sorted based on their relative fluorescent intensity to isolate DNA-bearing 
samples.  A 500 µL syringe pumped oil into the storage device at 2-3 µl/min to drive droplets 
from the storage device onto a simple Y-junction sorting device (Figure 3-3). A second 10 mL  
Figure 3-3: Schematic of the fluorescent activated droplet sorting device 
The microfluidic device for florescent activated droplet sorting  (FADS)is detailed.   These 
devices are fabricated to 100 µm depth, with  standard channel widths of 100 µm in all regions 
except the  inlets and the sorting region.  At the sorting region, the channel flares outward to 650  
µm and a series of pillars centered initially 250 µm from the upper edge create an asymmetric 
division for dielectrophoretic sorting. During operation, oil is  infused at inlet (A) to re-space 
small, 1 nl droplets re-injected into inlet (B).  These droplets flow past an interrogation point 
right before  the sorting region, where salt water electrodes allow the application of high voltage 
AC fields across the sorting region while marinating ground potential around the droplet inlet to 
enable  dielectrophoretic sorting of the re-injected droplets.  Droplets exit the device through one 




syringe infused oil onto the same device at 8-10 µL/min to respace these droplets as they entered.  
The device was set on a Nikon TS2 florescent microscope with a 10x objective aimed at the 
sorting junction. To detect the fluorescence of these droplets, we attached an Avalanche 
Photodetector (APD) from Thorlabs (410A2) to the eyepiece of our microscope using a c-mount 
Nikon 38mm eyepiece adaptor (LMscope). This APD outputs an analog signal corresponding to 
the light intensity that strikes the detector.  The existing microcontroller software was modified 
to operate in “FADS mode”. The analog voltage readout from droplet signals was sent through a 
12-bit ADC input to a STM32F407 ARM Cortex M4 microcontroller board (Mikroelektronika 
1685) running custom software.  The microcontroller software used an RTOS that acquired 
analog input signals from the APD and used a peak detection algorithm to identify droplets as 
signals above a user-defined threshold input on custom Labview software.  Peak voltage 
thresholds were set manually based on the observed readout from droplets passing the detector 
window.  The excitation wavelength for FADS was a 470 nm LED, and a 525 nm Nikon FITC 
filter cube was used to filter the emission. 
A digital output was used to control the DEP sorting voltage. This signal is buffered by a 
driver integrated circuit (Infineon IR2125), which selectively applies 5V power to a 1.5 kV AC 
30 kHz  CCFL  inverter board (JKL BXA-601). The outputs of the CCFL inverter were wired in 
parallel and connected through two 100k resistors in series to the sorting junction electrodes via 
a 3 M salt water filled syringe.  The microcontroller runs software written in C using Eclipse and 
ChiBiOS RTOS libraries and was interfaced via USB to control software written in Labview on 
the host PC.  When a peak was registered above the threshold intensity, the DEP sorting voltage 
was triggered, pulling the detected droplet into the upper outlet channel. Sorted droplets were 
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collected in 1.5 mL Eppendorf ® tubes and transferred with a pipette into a second glass storage 
tube for reagent addition. 
3.2.7 Single PCR Droplet Sequencing 
To sequence the contents of PCR amplified droplets, single droplets were captured in 
PCR tubes during the FADS sorting process.  This was achieved by moving the FADS outlet 
tubing rapidly between PCR tubes as the sorting occurred.  To ensure capture of single droplets, 
the flow rate of the FADS sorting was reduced from 2 µl/min to 0.5 µl/min.  With droplets of 
approximately 1 nl and a droplet DNA occupancy of approximately 1 in 10, fluorescent droplets 
are sorted and exit the outlet tubing approximately once per second. The relatively low frequency 
of PCR amplified droplets, combined with the minimal dwell time in each PCR tube enabled the 
capture of single exiting droplets in single PCR tubes.  Tubes containing single droplets were 
identified after deposition using fluorescence imaging to confirm single occupancy.  20µl of 
PCR master mix (prepared as described in 3.2.3) was then added to each tube identified as 
containing a single fluorescent droplet.  The single droplets were merged with this PCR mix 
through the addition of 1 µL of perfluorooctanol (PFO) to the PCR tube.  PCR reactions were 
amplified using M13_Long_For and pUC_57_Rev primers and Q5_Bulk PCR protocol before 
being sent to Genewiz (South Plainfield, NJ) for Sanger sequencing.   
3.2.8 Preparation of ivTT for in-Droplet Expression  
In-Droplet enzyme reactions were run by expressing transaminase DNA using New 
England Biolab’s PureExpress (ivTT).  1 mL of cell free expression buffer was created from 400 
µL and 300 µL respectively of ivTT solutions A and B, 40 µL of RNAse inhibitor (Murine, 
NEB), 40 µL of 2.5 mM PLP in 10 mM TRIS buffer, 20 µL of nuclease free water, and 100 µL 
each of 10, 50, or 100 mM of 1-(imidazo[2,1-b]thiazol-6-yl) propan-2-amine and equimolar 
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pyruvic acid in 10 mM TRIS (pH 7.5).  Final samples contained 1, 5, or 10 mM substrate amine, 
100 µM PLP, and 1, 5, or 10 mM pyruvate.    An identical 250 µL solution of expression buffer 
was created for the marker droplets used to track samples in the MADS workflow
80
 with the 
addition of 2.5 µL of 50 mM Carnitine and 2.5 µL of McCormick blue food dye.   
3.2.9 Addition of Digital PCR Droplets to ivTT Droplets  
Reagent addition was driven using a combination of gas pressure and syringe pumps to 
drive fluid flow on the droplet pairing device
20
 (Figure 2-8). A 500 µL Hamilton gastight syringe 
drove oil at 1.0-1.5 µL/min into the droplet storage chamber, driving droplets onto the device.  
The gas pressure pump (Elveflow OB1-MK2) was used to pressurize two vials to 3 psi (20.6 
kPa).  One vial held the perfluorinated carrier phase for ivTT droplet generation while the other 
held a 1.5 µL tube of ivTT solution.  The pressure on the vials created 30 nL droplets while the 
syringe introduced 1 nL droplet downstream at the frequency of droplet generation.  Paired 
droplets flowed past two channels containing 3 M salt water solution
107
 connected to a custom 
built high voltage inverter (CXA-L0512-NJL; TDK-Lamda) supplied with 12VDC and 
modulated by a potentiometer. High voltage applied to syringes connected to these salt water 
channels caused surfactant-stabilized droplets to merge as they passed the on-board elecrodes.  
Exiting droplets flowed directly into a second, larger droplet storage chamber made from a 
Pasteur pipette and capped with Silicone plugs (Figure 2-2).   
3.2.10 Droplet Storage and MADS Operation 
After DNA addition, droplets were incubated in the larger storage chamber for between 4 
and 18 h in circulating perfluorinated oil
120
 at room temperature.  Marker droplets made from 
dyed ivTT were added at the outset of incubation such that approximately 20% of incubated 
droplets contained the marker material.   
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After incubation, droplets were infused from the storage chamber and onto the MADS 
device. A 1 mL syringe filled with carrier oil was connected to the storage chamber and a 10 mL 
syringe containing carrier oil was connected to the MADS device.  Oil infusion from the 1 mL 
syringe drove droplets from the storage chamber onto the MADS device where oil from the 10 
mL syringe respaced them and drove flow on the MADS device.  Using an Elveflow OB1-MK3 
pressure pump, the outlet vials of the MADS device were pressurized to 0.8 PSI and the pre-
sorting oil inlet flow was driven using an oil-filled vial pressurized to 1.2 PSI to balance the back 
pressure of the droplets running to the mass spectrometer.  To ensure equal flow to the mass 
spectrometer and the sorting region on the microfluidic device as the system filled with samples, 
these pressures were ramped manually over the first 5-10 min of operation, in increments of 0.2-
0.4 PSI from starting conditions of 0.2 PSI and 0.0 PSI respectively. 
During screening, the mass spectrometer was set to monitor four ion channels: Amine 1-
M/z=182, Carnitine-M/z=162.3, Neostigmine-M/z=223, and chlorocholine-M/z=122.3. Amine 1 
was monitored to determine enzyme turnover in droplets, Carnitine was monitored to track 
droplet signals from dyed markers, Chlorocholine was monitored to track positive control 
droplets and determine baseline selection criteria, and Neostigmine was monitored to identify 
droplets containing library DNA.   
3.2.11 DNA Recovery from ivTT 
Following MADS sample sorting, collected hit droplets were pooled in a PCR tube and 
diluted with the addition of  20 µL 5mM Hepes Buffered Saline (HBS, 5mM HEPES, 20mM 
NaCl, pH 7.3) and 2 µl perfluorooctanol.  The resulting dilution was then filtered on a ZYMO 
spin column using the “PCR product” protocol and eluted in 10 µL of nuclease-free water.  This 
was used as template in a subsequent PCR containing 1 µL of recovered DNA, 10 µL Q5 2X 
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master mix, 8.6 µL of nuclease free water, and 0.2 µL each of forward and reverse primer 
(M13_Long_For, pUC_S7_Rev, 10 µM). This PCR reaction was carried out following the 
Q5_Bulk protocol in Table 3-1, and purified on a ZYMO DCC column.   
3.2.12 DNA Sequencing 
Recovered DNA fragments from ivTT were assembled into pUC57 vector using Gibson 
assembly to vector backbone amplified using primers M13_For_Long_RV and 
pUC_S7_Rev_FW, as previously described (3.2.4). After assembly, the vector was transformed 
into E. coli (NEB 10β) with electroporation, and cells were plated and allowed to grow on solid 
media overnight.  After colony growth, colonies were selected and diluted in 100 µL of liquid 
broth.  2 µL of the resulting broth were then used as template in a 25 µL PCR reaction containing 
12.5 µl OneTaq Hot Start 2x Master Mix (NEB), and 200 nM NEST forward and reverse primers 
following the “Colony PCR” protocol.  The PCR product of this reaction was sent to Genewiz 
for Sanger sequencing using T7 For and T7Term primers (Table 3-3). 
3.2.13 Device Fabrication 
Microfluidic devices were fabricated using standard soft lithography techniques 
104
.  
Devices were designed using AutoCAD software (Autodesk) and printed onto mylar film masks 
at 25000-50000 dpi (Fineline Imaging).  Using these masks, SU-8 2075 (Microchem Corp) was 
patterned to a depth of 200 µm on a 7.62 cm (3 in) diameter silicon wafer (University Wafer).  
PDMS (RTV 615, Curbell Plastics) was prepared in a 1:10 ratio of activator to monomer, poured 
over the wafers and cured 1 h at 70 °C before it was removed from the mold and hard baked for 
1 hour at 120°C.  Punched ports were created in the cured PDMS using a sharpened 20 or 22 ga 
syringe needle (BD) and the punched holes were cleaned by passing a short length of fused silica 
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capillary (360 µm OD, 20 µm ID, Molex) through the hole to clear any particulate left behind by 
the punch.   
Devices were cleaned with Scotch tape (3M) and bonded to 7.62 cm long (3 x 1 in) glass 
microscope slides (Corning) after exposing both the slide and the molded PDMS to oxygen 
plasma using a Tergeo plasma cleaner operating using the “PDMS Bonding” default protocol.  
Bonded devices were placed in an oven to cure overnight at 80 °C.   
3.2.14 Data Analysis 
Raw signal data from droplet MS screens was exported to .CSV files after screening, with 
one CSV produced for each monitored ion.  These files were collated into a single spreadsheet 
listing the timestamp and peak intensity of each of the 4 channels.  Peak heights for each droplet 
were identified by reporting maximum values above a user-defined threshold, and droplets were 
then automatically categorized based on their intensities using an excel spreadsheet.  Amine peak 
values classified as belonging to blank, library, marker, and control populations were then 
extracted and plotted using GraphPad Prism.  
While this data plotted does not directly represent the data observed by the 
microcontroller sorting the droplets in the MADS system, it gives an accurate representation of 
the droplet signals observed by the microcontroller.  The microcontroller receives an analog trace 
directly from the mass spectrometer, and makes its determination on what constitutes a peak and 
how that peak is categorized based on the minimum peak height thresholds set by the operator 
during the sorting process.  Data plotted after a screen is reported by the chemstation software as 
an ion count signal, rather than an analog voltage on the mass spectrometer.  This data is 
processed similarly in excel, with peak detection performed by defining peaks based on ion 
count intensity above a set threshold in the amine channel, and then reporting the maximum 
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values in each channel corresponding to the identified peak on the amine channel. Plotted data 
represents a reasonable representation of the data observed by the MADS hardware, but because 
one peak detection threshold is set based on the analog signal from the MS and the other based 
off of the ion count data stream, the magnitude of this threshold is slightly different.  Ultimately, 
the impact is that it is possible for these two processes to mismatch on the decision to categorize 
a peak as a droplet if a signal falls below the threshold of one but not the other, but practically 
speaking this is exceedingly unlikely, because the signal to noise in the peak identification 
channel – that of the amine– is sufficient to ensure that the threshold set for peak identification is 
reached by all droplets, and is well above any baseline signal on that channel. 
   Due to the slow transfer of substrate between active and inactive droplets, droplet 
populations monitored over several hours exhibited signal drop that followed the activity of the 
enzyme expressed within active droplets.  This decay was fit with quadratic functions to describe 
the spread of population data as the enzyme turned over substrate to product.  95% confidence 
intervals for this fit were calculated using graphpad software, and 95% prediction intervals were 
calculated and plotted as well.  These best-fit functions were used to assess the sorting metrics 
chosen for each population, analyze the sorted samples, and confirm the confidence with which 
hits were identified. 
3.3 Results: Implementation of an in-Droplet Protein Expression Workflow  
Previous examples of enzyme evolution in droplet microfluidics have relied heavily on 
protein expression in vivo, which limits the breadth of droplet screening to cell permeable 
compounds and non-cytotoxic proteins
32,73,76,89,91,114,121
.  In our earlier demonstration of in-
droplet transaminase activity monitoring, we were able to observe successful conversion of the 





. Given our ability to observe a distinct difference in amine substrate signal 
between droplets and bulk reactions that had received a dose of purified DNA and those that had 
not, it was now important to verify that this change in amine signal could be produced through 
in-droplet expression, and that this expression could be produced via the addition of unpurified 
PCR product in the droplet form.   
3.3.1 Design and Optimization of PCR Amplification in Droplets 
Similar to single cell protein expression and single cell encapsulation in microfluidic 
droplets, in vitro protein expression and evolution in droplets requires the delivery of single 
enzyme variant DNA to each microfluidic sample to produce unique proteins in each droplet. 
Stochastic loading of dilute solutions of DNA into droplets would enable single-gene, single 
droplet capture of DNA, but to generate sufficient concentrations of genetic material for in vitro 
protein expression, PCR must be used to amplify this isogenic material prior to ivTT 
expression
40,78
. This means that to perform in-droplet expression, we needed to combine single 
droplets of PCR product into single droplets of ivTT to observe enzyme activity.   
PCR is a well-established protocol for the amplification of DNA, but the degree of 
amplification, purity of product, and concentration of the DNA produced are intrinsically linked 
to the template concentration, number of cycles performed, and polymerase enzymes used in the 
reaction mix.  We needed to design a PCR protocol that enabled us to a) amplify single genes in 
single droplets without significant side products, b) track single gene amplification within each 
individual droplet to gauge the appropriate concentration of template to add, and c) track the 
ultimate addition of DNA to the ivTT solution using an added small molecule.  
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Figure 3-4: Experimental data and str  ategies for PCR amplification in droplets 
(A) PCR efficiency was lower when using PCR mix for digital qPCR than it was when using 
PCR mix for high fidelity amplification.  Q5 master mix (lanes 1 and 2) gives far more efficient 
DNA amplification when compared to the master mix made for digital PCR by BioRad (lane 3).  
However, droplets made from Q5 master mix did not survive thermocycling. Mixing the two 
commercial master mix solutions (lane 4) resulted in droplets that were both stable and gave high 
concentration product. (B) Side products formed during PCR amplification of linear template led 
to the development of a “nested” primer strategy for PCR amplification. Linear fragment 
containing the gene of interest is formed from plasmid template using NEST primers.  This 
template is distributed into droplets where it is amplified by EXT primers for expression.  The 
EXT amplified fragment is then recovered and amplified for sequencing using M13 and pUC_S7 
primers. (C) EXT primers amplifying NEST template in droplets gives clear, clean, single-
product signal around 1500 kb (marked with white arrows).  A dilution of 0, 50,  100,  200, and 
1000 fg per reaction shows increasing product formation with increasing template loading. 
 
PCR amplification in droplet format proved to be a challenge to the implementation of in-
droplet expression.  In particular, droplet stability during PCR thermocycling proved 
problematic, as was the appearance of secondary PCR products in the PCR reaction. Initially, we  
found that PCR droplets did not survive thermocycling when the PCR reaction mixture was 
made solely using NEB’s Q5 High Fidelity 2x Master Mix, but they appeared to survive when 
made using BioRad ddPCR Supermix for Probes (no dUTP).  We then found that the BioRad 
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master mix appeared to give less efficient PCR at the low template concentrations necessary for 
digital PCR to achieve single-droplet template loading. By combining these two solutions, we 
found we could achieve both droplet stability, and successful amplification (Figure 3-4 A).  
During these investigations, we noted the formation of multiple PCR products, especially when 
the primers used to amplify the linear sequence of DNA were the same as the ones used to build 
the linear fragment initially.   We found that we could eliminate this by utilizing “nested” 
primers for our gene of interest which successively moved inward on the template strand with 
each round of DNA amplification. Nested primer sets (which were reportedly used in previous 
droplet PCR protocols
40
) reliably gave clean product when successive PCR was performed on 
linear template (Figure 3-4 C). The first set of primers, NEST_FW and NEST_RV, bracketed the 
gene of interest 223 and 295 bases from the start and stop codon of the transaminase gene on our 
pUC-57_ATA117 construct.  These were used for the library build, and formed the initial linear 
gene fragment that would be purified and dispersed into droplets.  The second set of primers, 
EXT_FW and EXT_RV, laid 25-35 bases internal to the NEST primers.  These were used for the 
in-droplet PCR amplification, and would be what was expressed in the ivTT reaction. A third set 
of primers, M13_Long_FW and pUC_S7_Rev, could then be used to recover DNA from the 
ivTT reactions and regenerate the vector for cloning and sequencing hit sequences.  
3.3.2 Detection of PCR Amplification in Droplets 
To fluorescently track in-droplet PCR and template distribution, two approaches were 
explored.  Initially, quantitative PCR (qPCR) probes, which use the 3’  5’ exonuclease activity 
of Taq polymerase to degrade a sequence-specific oligomeric probe and release a quenched 
fluorescent signal, were used to detect PCR amplification.  However, these probes tended to 
disrupt full-length gene amplification in the droplet format, and PCR efficiency was low in  
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Figure 3-5: Strategies for detection of PCR amplification in droplets. 
(A) In early investigations, we found that the presence of qPCR probe in the PCR reaction 
greatly disrupted PCR amplification, but that SYBR Green dye, a small molecule that is 
fluorescent in the presence of double stranded DNA, did not.  (B) While probe-based detection 
gave positive signal for DNA amplification, the signal to noise was weak relative to what could 
be achieved with full probe cleavage by DNase (C), and the signal to noise of SYBR Green in 
PCR amplification (D) is higher, making DNA bearing droplets more easy to detect. 
 
reactions containing this probe material (Figure 3-5 A).  Furthermore, the release of the 
fluorophore within these droplets was far less efficient than expected, and the background 
fluorescence of unreleased probe was relatively high, likely due to the fact that the Q5 
polymerase that made up 75% of the reaction mix, does not contain 3’  5’ exonuclease activity 
(Figure 3-5 B).  SYBR
TM
 green I, an intercalating DNA dye, proved to be a better sensor for 
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DNA replication.  This dye is fluorescent only in the presence of double stranded DNA 
(dsDNA), so upon amplification, PCR product solution turns brightly fluorescent (Figure 3-5 D).  
The small molecule neostigmine was also added to the PCR reaction mix, which allowed the 
mass spectrometer to track addition of PCR mix to the microfluidic droplets of ivTT (final 
concentration 2.5 mM).   
Preliminary calculations that assumed an average per-base molecular weight of 330 
g/mol and a DNA strand length of 1500 base pairs  were used to estimate how much DNA was 
necessary to load into the PCR solution to get microfluidic droplets (assuming a 1 nL total 
volume) where approximately one in ten contained DNA (λ=0.10
122
 in Poisson distribution 
statistics).  This calculation showed that DNA would need to be diluted to low fg levels to 
achieve single droplet occupancy. While this gave a reliable estimate for how much it was 
necessary to dilute template DNA in PCR reaction mix, a dilution series of the template DNA in 
PCR master mix was performed each time digital PCR experiments were run, to determine the 
appropriate dilution for any given droplet PCR run.  This is because the concentration of the 
DNA stocks measured after purification are measured at significantly higher concentration than 
the dilution necessary to achieve single droplet loading in droplets (in the ng/µl range), and the 
dilution necessary to bring each stock to single occupancy concentrations tended to vary between 
10 and 100fg, likely due to the limitations in the spectrophotometric read of the starting DNA 
concentration and DNA loss to the surface of the pipettes and tubes with which stocks were 
diluted.  
Typically, we aimed for an encapsulation ratio (λ) of λ=0.10
122
, or 0.10 DNA molecules 
per droplet.  At this dilution, 90% of droplets should receive no DNA, and of those that do, 90% 
should receive only a single copy of DNA, with the remaining 1% of droplets getting 2 or more.   
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Figure 3-6:Flourescent images of digital PCR dilutions  
Digital PCR at a range of template concentrations reveals the stochastic loading of droplets with 
PCR template prior to PCR.  At low template concentrations, single template strands of DNA are 
captured in single droplets and amplified to give a high concentration of DNA, all stemming 
from a single parent sequence. 
 
Figure 3-6 shows a representative dilution series. Typically, a dilution series such as this was 
used to set the concentration for digital PCR, with the aim being to select the concentration 
closest to the desired 10% occupancy.  PCR protocol Q5_Droplet was used to amplify the 
droplets during digital PCR. 
3.3.3 Expression of PCR Reaction Product by ivTT 
To test the ability of our ivTT reaction mix to express unpurified PCR-amplified DNA 
and exhibit a drop in the signal of amine 1, a set of bulk 25 µl ivTT reactions with varied 
template loading were performed at microliter scale.  1 µL of water, purified T7 promoted 
epidermal growth factor receptor protein (EGFR) template (125 ng/µL), and de-emulsified 
ddPCR master mix amplified in droplets with 0, 10 fg, 100 fg, 1 pg, or 2 pg of linear template 
(per 20 µL reaction) was added to each.  After 6 h at room temperature, the reactions were 
analyzed via direct mass spectrometry of infused plugs (see 3.5.12), monitoring the mass of the 
substrate amine (1) (Figure 3-7).  The addition of droplet PCR-amplified DNA to the ivTT 
reactions resulted in a decrease in amine signal (p<0.001) for all samples receiving more than 10 
fg/reaction of DNA amplified in droplets.  The addition of PCR mix that did not have template 
and PCR mix with very low template concentrations (10 fg/reaction) allowed confirmation that 




Figure 3-7: Bulk ivTT reactions reveal enzyme activity as a drop in amine signal 
Amine signal read by direct MS of droplets of ivTT reaction solution. No expression, and 
expression of an inactive protein (columns 1-3) result in a high concentration of amine substrate 
remaining.  Expression of the transaminase ATA117 gene in bulk results in a distinct decrease in 
signal.  The extent to which this decrease occurs corresponds to the quantity of transaminase 
DNA added.  When low template concentration of 10 fg/reaction is used, ~90% of droplets are 
empty, and the dilution of template that occurs when the droplet PCR emulsion is broken is 
sufficient to result in insufficient DNA expression for activity to be observed via loss of amine 
substrate. Images inset below the bars reveal the occupancy of PCR amplified droplets when 
fewer than 100% of droplets receive template DNA. 
 
amount of DNA was necessary to express enough protein to observe amine signal decrease. The 
expression of EGFR DNA in the same reaction conditions (EGFR protein has no transamination 
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activity) confirmed that this drop in substrate concentration stemmed from the presence of 
transaminase DNA being expressed, not merely DNA expression. 
3.3.4 In-Droplet Expression of PCR Reaction Product by ivTT 
Confirmation that protein could be expressed in single droplets from digitally amplified 
droplets of DNA was undertaken by confirming transaminase expression after reagent addition 
of digital PCR material to ivTT.  Diluted NEST-amplified ATA117 template was added to PCR 
master mix and thermocycled so that each amplified droplet would contain (and therefore induce 
expression of) the same template DNA.  Using a dilution of 5 fg of template in 20 µL of PCR 
master mix containing 2.5 mM neostigmine, NEST_ATA117 was amplified in ddPCR and added 
to 30 nL droplets of ivTT.  After incubating 6 h, these droplets were infused onto the mass 
spectrometer using the MADS device. 
Figure 3-8 shows both the experimental workflow and the resulting populations of 
droplets and their substrate amine signals. Transaminase expression could occur only when 
ddPCR samples containing amplified DNA were added to droplets of ivTT, and the addition of 
ddPCR material was traceable independent of protein expression in the form of neostigmine in 
the added PCR material.  As before, DNA expression and subsequent transamination could be 
observed using MS monitoring of amine 1, while successful addition of PCR materials could be 
observed by monitoring the neostigmine from the PCR solution.  If the proportion of droplets 
displaying a change in amine 1 signal matched the proportion showing fluorescent labeling after 
digital PCR, this would suggest successful expression from singly amplified droplets of DNA  
As expected, a reduction in in amine 1 signal was observed when the added ddPCR droplet 
contained amplified and expressed ATA117, and the frequency of this result closely matched the 




Figure 3-8: Experimental workflow and data for single gene droplet expression  
 (A) The experimental workflow for determining if single droplet expression is possible from 
PCR amplified DNA in droplets is shown.  DNA is diluted to 5-10 fg per 20 µl PCR reaction and 
neostigmine is added to the mixture before it is broken into 1 nl droplets.  After PCR 
thermocycling, amplified DNA will only appear in droplets that contained single template 
strands of DNA prior to amplification.  These droplets are then added to droplets of ivTT with 1 
mM of the substrate amine 1, and the signal of the droplets after 4 h of expression is read via 
droplet MS.  The small molecule neostigmine in the PCR reaction allows the addition of single 
droplets of DNA to droplets of ivTT to be tracked via mass spectrometry. (B) When the 
neostigmine and amine signals in each droplet are plotted against one another, distinct 
populations of droplets may be identified.  Droplets that receive no addition through the reagent 
addition process show low neostigmine signal, as there is no neostigmine in the ivTT and it only 
can be added through reagent addition.  Because these droplets have undergone no addition, they 
all have high amine signal, corresponding to no enzyme activity.  The population that received 
amplified DNA droplets from the reagent addition process show a reduction in the amine signal 
and an elevated neostigmine signal (blue region), while those that received empty droplets 
without DNA amplified within show an elevated neostigmine signal but no reduction in the 
amine signal.  The ratio of the droplets containing DNA as observed in digital PCR fluorescent 
imaging (inset) closely matches the proportion showing activity within the expressed droplet 
pool.  Addition of two droplets of DNA to one of ivTT may also be observed in the two clusters 
of droplet signals to the right of the red and blue highlighted clusters, showing that neostigmine 
concentration scales with addition volume.  This also explains the scatter along the x axis 
between clusters – reagent addition is not 100% consistent and some droplets will receive more 
or less than a single volumetric addition, either due to size variation within the DNA droplets, or 
due to pairing of more than one droplet to each ivTT sample. 
 
result indicated that ivTT expression of isogenic DNA was indeed occurring in droplet samples, 
and that this translated directly into a reduction in the amine concentration. 
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3.3.5 SSM Library Generation  
To screen for transaminase enzymes capable of outperforming the wildtype enzyme in 
the transformation of amine 1, a site saturation mutagenesis (SSM) library of transaminase 
variants (see section 3.2.4) was built and screened for activity. This library of enzyme gene 
variants was cloned into the plasmid pUC57 and evaluated for the appropriate diversity (Table 3-
4) through E. coli expression and Sanger sequencing. 69% of the sequenced colonies displayed 
expected library SSM mutations, and 6% carried the parent (WT) gene, with the remainder 
showing more than one mutation or frameshifts. This library of gene fragments encompassing 
the first tier (Table 3-2, representing 1,919 enzyme variants from saturation mutagenesis of 96 
positions in the enzyme core) was then used as template in droplet PCR for single droplet library 
amplification.   
 
Table 3-4: Wildtype Tier 1 library Sequencing  
Library quality control data for the SSM build off of WT transaminase shows the  majority of 
sequences read show expected, single-site mutations on the DNA sequence, all at targeted SSM 
locations. 
 
3.3.6 Fluorescent Activated Droplet Sorting to Enrich for DNA Expression 
Droplet expression data from early work on the expression of PCR amplified ATA117 
DNA highlighted a key challenge in the execution of single droplet protein library expression.  
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Due to the initial distribution of low copy number DNA into PCR droplets, the majority of PCR 
amplified droplets will contain no DNA after amplification, and will therefore demonstrate no 
activity upon addition to ivTT solution.  To maximize MADS sample processing rates, 
enrichment of library DNA in the DNA bearing ddPCR droplets was necessary prior to ivTT 
expression.  A microfluidic device for fluorescent activated droplet sorting and used FADS 
enrichment to isolate droplets with DNA after PCR was therefore developed tosort the samples 
based on SYBR green fluorescence.     
PCR amplified droplets containing WT library DNA were sorted using this FADS setup 
(Figure 3-3). Without sorting, only 14% of these droplets are fluorescent and have the potential 
of containing the DNA for an active (or inactive) variant.  While many of these droplets should 
contain DNA coding for active mutations, the nature of an SSM is such that some of these 
droplets will code for deactivating mutations, and unlike the PCR experiment in Figure 3-8, 
fewer than 14% of these samples should be active when expressed.  These droplets were sorted 
by their fluorescence, and imaged before and after sorting to verify accurate FADS enrichment.  
Bulk enrichment of the DNA in sorted droplets was also confirmed via gel electrophoresis 
(Figure 3-9 B).  Fluorescent images show enrichment to 97% fluorescent from 14%, and a 
significant increase in signal intensity on the gel after sorting (Figure 3-9 B, lane 2).   
The expression of unenriched library DNA should show far fewer active samples than 
that of the FADS enriched library DNA, and that the number of active samples in the unenriched 
pool should be less than 14%, due to the nature of the SSM library, which will exhibit both 
deleterious and advantageous mutations. In the instance shown in Figure 3-9 C and D, only 7.5% 
of expressed library droplets initially showed signal within the 95% prediction interval of the 
WT activity distribution. This prediction interval is an attractive estimate for activity within 
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library samples, because it represents the activity distribution of the unmodified, wildtype 
enzyme.  
 Given that only 14% of droplets showed fluorescence prior to sorting, but 97% showed 
fluorescence after, a commensurate increase in the number of signals showing enzyme activity 
should be observed after sorting. Following FADS enrichment, 60% of droplets in the library 
appeared within the 95% prediction interval of the wildtype positive control, an 8-fold increase 
that closely aligns to the fold-increase in fluorescent droplets (Figure 3-9 E and F).  This result 
demonstrated the effect of pre-sorting DNA droplets; doing so minimized the number of empty 
droplets processed by the MADS system.  
The utility of eliminating these empty samples is best understood through an assessment 
of the time and cost of the alternative to fluorescent sorting.  Without sorting, ivTT samples  
would receive DNA for expression 14% of the time, meaning it takes approximately seven times 
as much time to read a single sample, and seven times as much ivTT.  Fluorescent sorting (at 
current rates) for this work took approximately 16 h  per screen, due to the low per-droplet 
volume (1 nL), relatively low speeds (50 droplets/s)  and the high emulsion volume (~100 µL) 
necessary to run the reagent addition device.  This meant that a screen over an 8 hour day with 
FADS sorting took three times as long as one without, but covered 7-8 times  as many samples 
and saved 7-8 times the volume of ivTT, leading to a reduction of a week of screening time and a 
cost savings of several hundred percent.  Given the expense of the ivTT material used in this 
screening workflow, this is a significant factor in the decision to pursue pre-enrichment of 
droplets with DNA. 
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Figure 3-9: Fluorescence activated droplet sorting enriches DNA containing droplets 
 (A) Representation of Fluorescent Activated Droplet Sorting (FADS).  This technique enables 
the enrichment of DNA containing droplets prior to reagent addition in the droplet format. A 
microfluidic device allows 100-125 µm, ~1 nl droplets to be reinjected at 1-2 µl/min into a 100 
µm channel and separated by re-spacing continuous phase.  As these droplets flow past an 
illumination and detection point, they are interrogated serially by an avalanche photodetector, 
which is used to trigger a sorting pulse on downstream electrodes.  (B) Imaging before and after 
sorting reveals enrichment for droplets containing DNA from 14% to 97% fluorescent, and gel 
electrophoresis confirms the higher intensity of signal (and therefore enriched DNA 
concentration) in sorted droplets. Panels C, D, E, and F show the distribution of droplet activity 
(measured by the reduction of amine) in a library of samples prior to fluorescent sorting of the 
expressed WT library (C/E) and after sorting (D/F).  Both reactions were performed with 10 mM 
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Amine and read starting at 4 h after reagent addition.   95% prediction intervals in E and F mark 
the region expected to contain 95% of signals with wildtype activity. Fluorescent enrichment 
increases the percentage of library samples that fall within this plotted region from 7.5% in (E) to 
60% in (F). This demonstrates that pre-enrichment with fluorescent sorting enriches the number 
of active samples read  within a single library screen by nearly 8-fold. 
 
3.3.7 Single Droplet Sequencing Enables Sequence Confirmation 
To test the contents of PCR amplified droplet, single droplets were captured in PCR tubes 
during the FADS process (Figure 3.3.6).  These single droplets were then merged with 20uL of 
PCR master mix and underwent PCR amplification (Figure 3-10), followed by Sanger 
sequencing.  73 droplets were read this way, with 55 giving full reads.  Ideally, the sequence 
distribution read this way would closely match that of the original library material, with around 
70% of the reads carrying a single site mutation.  DNA loading into the droplets will follow a 
Poisson distribution, and the statistics for single gene encapsulation are such that the number of 





The probability of a droplet containing X DNA sequences is given by the term λ, which 
measures the number of DNA strands available in the original solution, per droplet volume 
(copies/drop).  With 14% of droplets showing fluorescence, it is possible to back-calculate that 
this λ value was approximately 0.15 DNA sequences per droplet, which closely matches the 
observed number from a dilution of template to approximately 5 fg/reaction (0.16)  (Figure 3-6).  
This value of λ may then be used to calculate the fraction of the fluorescent droplets with DNA 
that will contain a single strand, in this case 92% of our samples.  Given the distribution of 
wildtype, SSM, and truncated sequences observed in the original library sequencing, single gene 
encapsulation should occur approximately 64% of the time  (70% library multiplied by 92%  
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Figure 3-10: Single droplet sequencing data for amplified DNA in droplets  
(A) Fluorescent activated droplet sorting enables the capture of single droplets in PCR tubes.  
Brightfield and fluorescent images show these single droplets in PCR tubes, which have been 
highlighted with red circles.  These single 1 nL droplets may be combined with PCR reagents 
and amplified, enabling single droplet Sanger sequencing.  The table in (B) summarizes the 
results of single droplet sequencing, and reveals that after encapsulation and amplification, non 
SSM mutations (in red) are present in the DNA that were not present prior to amplification.  This 
tells us that while single droplet PCR is amplifying single gene variants within 1 nL droplets, the 
process is not producing isogenic droplets with perfect fidelity.  Ongoing work seeks to resolve 
this. 
 
 single capture), and wild type DNA approximately 8% of the time, with the remainder carrying 
mixed materials. 
Single droplet sequencing results (Figure 3-10) revealed that among the 55 full reads, 
20% (11 reads) showed the parent DNA. 33% (18 reads) showed library members with single 
site mutations. 47% (26 reads) show multiple mutations or mixed sequence reads at a single 
mutation site, a phenomenon that could be caused by multiple gene encapsulation, PCR droplet 
merging, or mutation during amplification.    
The high frequency of mixed mutations was concerning, given the statistics of droplet 
encapsulation and library composition previously gathered.  Further investigation of the 26 
sequences containing multiple or mixed mutations reveals that 14 contained mutations not 
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explained by the NNK library build, which only targeted 96 sites using an NNK degenerate 
codon system that should ensure that the final nucleotide of any mutant codon is a G or T. Only 2 
(4% of the total reads) sequences contained clear evidence of multiple NNK codons in a single 
read, and 9 showed evidence of mixed sequence at a single mutation site. Taken together, this 
evidence suggested that (1) the digital PCR process was introducing extra mutations into samples 
that appeared to have started as single NNK variants in single droplets, and (2) single gene 
encapsulation and amplification was occurring in the droplet context.  Investigation into the 
observed mutation phenomena described here is ongoing, and ultimately an important challenge 
to resolve.  Among other things, SYBR green degradation products have been shown to be 
potential inhibitors of PCR
123
, so further work optimizing the droplet reaction conditions and 
SYBR green concentrations could help resolve these issues. Nonetheless, single droplet 
sequencing provides an (as yet unreported) opportunity to gain insight into the genetic contents 
of droplets amplified in digital PCR, and this work enabled verification that the library 
distribution in droplet PCR produced isogenic amplified DNA for expression in droplets of ivTT.   
Even with the appearance of these non-SSM reads, 80% of reads showed non-WT DNA 
amplified within the droplets, and none showed more than 2 mutations on the WT sequence.  
Single droplet expression therefore appears to be capable of producing single protein expression 
in a microfluidic droplet. 
3.4 Initial Efforts to Screen a WT Transaminase Library 
With a procedure in place for the complete in vitro expression and activity assay of 
transaminase enzymes, we considered our potential ability to screen a library of enzymes using 
this system.  Analytical data from previous work with the MADS platform revealed that our Z’ 





, was negative when measured between the wildtype enzyme and the 
blank samples at the beginning of the reaction, though it did increase as a function of reaction 
time (Figure 3-11).  Typically, a strong screen will have a Z factor of 0.5 or better between 
positive controls (hits) and negative controls.  A negative Z’ means that the 99% confidence 
intervals of the two populations overlap and distinguishing the two populations with 99% 
confidence is not possible. Because positive enzyme variants (better than WT) will show greater 
separation from this baseline, and because the WT activity is a metric of minimal activity, not 
maximal for the transamination this suggested the MADS system would be capable of 
identifying WT activity or better.  Previous droplet calibrations (Figure 2-10) demonstrated that 
the mass spectrometer had the necessary dynamic range to see  samples outperforming the 
wildtype enzyme, and the Z score of a reduction from  1 mM amine 1 in ivTT to 50 µM in 
droplets was 0.757
80
,  suggesting that the screen contained the necessary sensitivity to see 
something better than wildtype, even if the difference between wildtype and blanks was not fully 
resolved. 
A library of transaminase variants built from the wildtype enzyme template was 
expressed and screened using the MADS workflow.  The linear library template material (NEST 
primer amplified) was distributed into droplets for ddPCR, amplified, and sorted according to 
our FACS protocol.  1 pg of the parent transaminase DNA was also amplified in PCR droplets 
containing 10 mM chlorocholine rather than neostigmine, and the droplets of parent DNA and 
sorted library DNA were mixed at a 1:8 ratio to create an addition pool coding for both the 
parent enzyme 12.5% of the time (marked with chlorocholine) and the library enzyme 87.5% of 
the time (marked with neostigmine).  A reaction solution containing ivTT, 1 mM Amine 




Figure 3-11: Z factor of the separation between WT and inactive droplet samples. 
Raw data from figure 2-12 is re-analyzed to assess the separation between the wildtype 
transaminase and the blank samples at the 1 mM screening conditions read after 4h incubation.  
Here, yellow and blue data points express the wildtype transaminase enzyme, and the separation 
between these samples and the samples not expressing active enzyme is given as Z factor for two 
regions of the plot.  This value measures how fully separated the two populations are relative to 
their analytical spread.  Typical screening conditions are optimal when the Z factor separating 
negative and positive controls is greater than 0.5, and the low Z factor between the WT and 
negative samples tells us that the WT enzyme is not separated enough from the inactive samples 
during the reaction for something with WT activity to be captured without the risk of capturing 
false positives.  Given that we were screening for enzymes more active than the WT parent, any 
such enzyme would be further separated from the inactive samples, and an initial screen of the 
WT library at these conditions was warranted. 
 
protocol described in chapter 2.4.3, the droplets of DNA were paired and merged with droplets 
of ivTT.  Collected droplets were then incubated 4 h and read on the MADS device.  
Data from the first attempt at library expression and assay is shown in Figure 3-12.  The 
raw signal from the amine trace was extracted for each droplet peak (See data analysis, 3.2.14), 
with droplet identity assigned based on the signal from neostigmine (library members) and 




Figure 3-12: Initial Screening results from the assessment of a transaminase library 
(A) Plotted amine signals for each of the approximately 8000 samples screened in the initial test 
of the MADS system for directed evolution.  Wildtype positive control samples are depicted in 
red, library samples in blue, and samples that had neither chlorocholine nor neostigmine (blank) 
in black.  95% prediction intervals, calculated from the quadratic fit of the blank and WT control 
populations, are calculated and displayed on the plot as shaded regions in the color of the sample 
data points.  These provide a rough metric of the data spread of these two samples.  Only two 
samples appear below the 95% prediction interval of the wildtype samples, suggesting that very 
little, if anything in this screen is outperforming the activity range that we would expect from the 
wildtype samples.  The red trace on this plot marks the running average of the wildtype samples 
in the data set, and a sorting ratio of 0.95 times the positive control average was used to collect 
anything below the light blue shaded region. These samples were recovered and the DNA 
sequenced. (B) Fourteen sequences recovered from these samples were tested in bulk ivTT 
reactions run for 4 h after the addition of 100 ng of DNA per 25µL ivTT reaction.  Each sample 
was then infused as plugs onto the mass spectrometer and the amine concentration read.  The 
signal intensity averages of these plugs is shown, with error bars showing the standard deviation 
in signal intensity (normalized to the wildtype control) for each plug (N>200 for all samples). 
None of the recovered sequences appeared to outperform the WT enzyme.  
 
the blank droplet samples and almost 2500 unique library samples were observed, only 2 of these 
samples were below the 95% prediction interval for wildtype signals (Figure 3-12 A).  During 
the screen of these library samples, we collected all samples that came out below 0.95x the 
positive control signal calculated from the running average of the last 16 wildtype signals (red 
line, Figure 3-12 A).  These were transformed into E. coli and colonies picked for sequencing.  
Sequencing revealed 89 different variants in 141 reads, suggesting that we had not particularly 
reduced the library diversity in this experiment.  15 variants appeared in more than one read, 
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including the parent enzyme, which was in 36 colonies sequenced (25%).  This was only slightly 
higher than the percentages observed in the single droplet sequencing (20%).   
Given the lack of convincing hit variants both in the plotted droplet data and in the 
sequence reads, 15 unique reads (including WT) that appeared multiple times in this sequence 
pool were assessed for activity.  None of the 14 selected variants produced more ketone than the 
WT enzyme when the reaction was run in bulk in a format emulating the conditions in the 
droplet: 1 mM amine and pyruvate in ivTT, with the read taken 4 h after the addition of 100 ng 
of DNA per 25 µL (Figure 3-10 B). 
3.5 Rational for Screening a Degenerate Transaminase  
Results from the initial SSM screen led us to consider the question: if we have two 
unique enzyme variants in our microfluidic system, can we differentiate their activity in droplet 
format?  Our initial attempt at screening had no true positive control towards which we could 
screen to confirm activity based selection.  To ensure that enzyme variants of differing activity 
could be accurately differentiated in this system, we tested the capability of the MADS 
electrospray platform to distinguish the wildtype enzyme from an enzyme variant containing a 
deleterious mutation.  We chose the mutation S17P, which was one of the 14 re-tested variants 
from our screen of the wildtype library, and showed approximately 50% reduced activity for the 
catalytic transformation (Figure 3-12).   
We began by observing the reaction of the S17P enzyme and the WT enzyme in bulk as a 
function of time.  If the S17P enzyme was indeed the weaker enzyme, we expected it would 
produce product more slowly, and reduce substrate concentration slower, than the wildtype 
enzyme.  Data from running the two reactions in bulk using previously established methods  
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Figure 3-13: Assessment of the deleterious mutation S17P in bulk and in droplets 
(A) Bulk reactions of the S17P and the wildtype transaminase variants were performed and 
quenched to reveal the slower product production in the S17P enzyme variant.  However, while 
product formation rates are clearly different in these two enzymes, the relative error in substrate 
signal made distinguishing the two by amine 1 concentration problematic. These bulk reactions 
made it clear that the current reaction conditions and measurement of the substrate loss was not 
viable for distinguishing the two enzyme variants.  (B) When the two enzyme variants were co-
expressed in droplets and screened at 1 mM substrate amine after 4 h incubation, we observed 
similar results.  Both variants show similar amine 1 levels and their 95% prediction intervals 
largely overlap, making amine concentration a poor metric for telling the two populations apart.  
We hypothesized that one potential challenge to distinguishing these two variants was the 
relative concentration of enzyme and substrate in the reactions.  
 
showed that this was indeed the case (Figure 3-13A), but that at the concentrations of the 
previously performed reactions (1 mM amine) it was difficult to observe a difference between 
the two when monitoring the amine signal drop.  This was also the case when the reaction was 
performed in the droplet format using reagent addition to droplets of ivTT (Figure 3-13B). 
We hypothesized that we might be able to better distinguish the two by optimizing the 
reaction conditions.  Typically, when biocatalysts are screened, it is necessary to optimize 
substrate concentration, reaction time, and enzyme concentration to ensure that a difference may 
be observed between two differentially active enzymes. It’s common to screen reaction 
conditions for the optimal enzyme or substrate loading that allows enzymes to be easily 
distinguished.  At low enzyme concentrations where substrate availability is far greater than 
either enzyme can fully utilize, a faster enzyme will demonstrate higher conversion of the 
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available substrate than its weaker counterpart because it will be capable of converting the 
available material at a higher rate.  If enzyme concentration is too high or substrate concentration 
is too low in a reversible reaction, both enzymes will rapidly reach the reaction equilibrium, and 
will no longer be possible to distinguish.  Because ivTT is being used to express droplets of 
DNA in the MADS system,  droplet samples’ protein concentration is not easily diluted for 
optimized screening conditions.  However, substrate concentration may be increased along with 
reaction time in order to maximize the separation between the S17P and the WT enzymes.  1 M, 
2.5 mM, 5 mM, and 10 mM amine concentrations were run and assessed both 4 h after reagent 
addition and 18 h after reagent addition.  It was determined that at a 10 mM Amine with the 
overnight reaction incubation, enough difference between the activity of the two enzyme variants 
existed to better resolve the two populations (Figure 3-14) when monitoring substrate loss. 
To investigate how fully resolved the S17P and the WT populations were with this 10 
mM, overnight reaction, and see if it was possible to screen a library of S17P variants for WT 
level activity, we calculated the Z’ for a screen at these new conditions, where the wildtype is the 
positive control.  With the higher amine and longer incubation, the Z’ of the separation between 
the WT enzyme and the negative control samples was 0.53 (Figure 3-14), significantly improved 
relative to the 1 mM, 4 h reaction conditions used originally (Z’=-0.17).  A hit with wildtype 
level activity from a library of samples whose activity falls between the negative and positive 
control should be completely distinct from the negative control population, with more than 6σ 







Figure 3-14: Improved conditions for screening differences between WT and S17P  
Difference in activity read in droplet samples expressing the S17P enzyme vs the WT enzyme 
after 18 h incubation at 10 mM amine 1 in the reaction.  The difference in enzyme activity read 
by the MADS system was tested at 1 mM, 2.5 mM, 5 mM, and 10mM amine and pyruvate, 
reading the reactions after 4 h and 18  h incubation. We determined that running the reaction for 
18h at 10 mM amine enabled us to more clearly distinguish the activity of the S17P and wildtype 
enzymes. At these conditions, the two populations still overlap, but the Z’ between the wildtype 
enzyme and the blank samples is 0.53, while the Z’ between the blank signal and the S17P signal 
is -0.54.  At this level of separation, WT level activity is clearly differentiated from blank 
samples but S17P is not.  This distinction should be clear enough to screen a population of 
samples whose most active members show WT level or greater. 95% prediction intervals are 
plotted for all three populations, to highlight that there is still some overlap between the WT and 
S17P population activities. 
3.5.1 Construction of a Degenerate Transaminase Library   
With a procedure in place for the in vitro expression and activity assay of transaminase 
enzymes in droplets and the confirmed ability to better distinguish two enzyme variants, we next 
aimed to show the MADS system’s ability to enrich a population of enzymes for those 
outperforming their peers.  We now had two enzymes with a single site mutation difference that 
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performed at two distinct levels and enzymes with the greater of the two activities could be 
completely distinguished (with more than 99% confidence) from the negative.  
With this in mind, we ordered a commercially built (Genscript) single site mutation 
library using the weaker S17P enzyme variant as the backbone.  This library consisted of the 
same 96 targeted sites screened during our initial screen of the WT enzyme, and was made up of 
1,919 unique sequences.  We assembled this library into E.coli for quality control and 
sequencing, and found it contained approximately 15% parent (S17P) sequence, and 67% SSM 
variants (Table 3-5).  This was on par with the in-house built library built from the wildtype 
ATA117 backbone. We performed digital PCR of the sample, as previously described.  
 
Table 3-5: S17P Tier 1 library sequencing 
Library quality control data for the SSM build off of the S17P backbone transaminase shows the 
majority of sequences read show expected single-site mutations on the DNA sequence, all at 
targeted SSM locations.  The number of single mutation sequences read in colony based 









Table 3-6: Single droplet sequencing of S17P library amplified in droplets 
Single droplet sequencing of 15 captured droplets from the unsorted S17P SSM amplified in 
droplets revealed a high rate of excess mutations on PCR amplified droplets, as had been 
observed previously.   The vast majority of these samples had received a single template from 
the SSM library build, but the template  received additional mutations during amplification.  One 
of the 15 samples showed the P17S reversion to wildtype, which we believe stemmed from the 
presence of background WT SSM DNA in the PCR mix. 
3.5.2 Single Droplet Sequencing Reveals DNA Droplet Composition 
Fluorescent sorting of the PCR amplified SSM library enabled us to perform sequence 
reads on single, fluorescently labeled amplified droplets after digital PCR.  In the case of the 
droplet sequences read prior to the screen of the S17P SSM library, we read 15 sequences at the 
dilution used for the library screening.  Of those 15 sequences, 3 showed the library backbone, 
an observation that closely matched the read of the library prior to encapsulation and PCR (Table 
3-6). 9 of these sequences had multiple mutations in the read, while only 2 had the desired single 
mutation to the S17P backbone. However, every single mixed sequence showed a combination 
of  a single SSM codon change  and a single non-SSM site mutation – a phenomenon which we 
had previously observed in the WT SSM.    This result suggested that 11 of the 15 had initially 
received library DNA, but that many of these experienced non-SSM mutation during the digital 
PCR process.  The 15
th
 sequence contained an SSM mutation built off of the wildtype backbone.  
Investigation of the blank control samples made in tandem (Table 3-7) revealed the likely source 
of this WT-A257G material to be background WT SSM material.   In 14 reads of fluorescent  
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Table 3-7: Droplet sequencing of S17P library blank reveals source of WT DNA  
Single droplet sequencing of 14 captured droplets from the blank PCR reaction amplified in 
droplets revealed the presence of background WT SSM material contaminating the PCR 
reaction.  All of these samples were WT SSM members.  Like the other single droplet 
sequencing results, these droplets exhibited a high rate of untargeted mutation. 
 
droplets collected from PCR samples to which no DNA template had been added, all showed the 
wildtype sequence at position 17, and 50% showed WT-A257G.  This discovery suggested that 
a) our droplet PCR samples had background signal from WT SSM DNA mixed in, and b) these 
PCR reactions contained 5-7% WT SSM members, and ~95% S17P SSM material.  
3.5.3 Single Droplet Expression and Sorting 
We fluorescently sorted the S17P SSM DNA amplified in droplets and performed single 
droplet expression of the S17P SSM DNA, using tandem expression of S17P isogenic DNA 
amplified in droplets (1 pg per 20 µL reactions) as a positive control.   Figure 3-15 shows the 
distribution of samples in the population from 7 h of read time, during which more than 14,000 
droplet samples were interrogated.  As expected, the library samples in the screen ranged broadly 
in amine signal, from the activity of the inactive samples to activity surpassing the active “S17P” 




Figure 3-15: Screening results from the assessment the S17P transaminase library 
Screening data from the selection of the library built off of the S17P backbone.  The running 
average of the S17P parent enzyme samples is shown in the red trace, with individual samples 
plotted in red.  Library samples expressing DNA variants built from the S17P backbone are 
shown in blue.  The shaded region of the plot represents the 95% prediction interval for wildtype 
samples, calculated from the quadratic fit of the WT sample data.  Unlike the initial wildtype 
SSM screen, these reaction conditions and library members reveal samples clearly outside and 
below the 95% prediction interval window, suggesting the presence of enzymes expressed that 
are better than the S17P parent.  The black trace follows the selection criteria applied to this 
library, which was any signal that appeared lower than 80% of the intensity of the average S17P 
signal These samples are highlighted above with circles drawn around them, and represent 
approximately 5% of the expressed library samples. 
 
During the screen, we used the running standard deviation from the S17P backbone 
average, which was actively calculated and reported by the MADS software, to set a selection 
threshold of 0.8x the S17P average, as this appeared to be approximately 2 standard deviations 
from the mean of the parent backbone sample.  This threshold, denoted as a black trace on figure 
3-15, consistently falls below the 95% prediction interval calculated off of the parent population 
(red shaded band) and served as a selection threshold stringent enough to capture enzymes 
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outperforming the parent S17P enzyme.  The hits whose signal appeared below this level were 
collected into a single pool of droplets, merged, and the DNA recovered.  Over the course of the 
screen, 286 of 5823 library members were identified as hits below this threshold, representing 
approximately 5% of the original population.  This matches closely to the expected number of 
WT sequences (6%) in the pool based off of initial single droplet sequencing results on the 
library. 
3.5.4 Assessment of Sorting Results 
Droplet sorting results were assessed using both sequencing and re-encapsulation and re-
screening the hit sequences.  For sequencing, hit DNA was assembled into vector pUC57 and 
transformed into E. coli for picking and sequencing.  Notably, 28% of all sequences in the 
collected pool of DNA exhibit the mutation P17S, a reversion that should have recovered the 
activity of the original wildtype enzyme. 52% of these P17S reversions bore the single site 
mutation A257G, the same mutation observed in 50% (7/14) of the single sequencing reads from 
the background signal.  This represents approximately 5-fold enrichment from the starting 
distribution observed by single droplet sequencing. 
Additionally, when the recovered population of samples was transformed into E. coli, the 
resultant DNA could be put back through the MADS workflow to assess the activity distribution 
of the population after enrichment.  This material, when FADS sorted and re-expressed in the 
droplet format, exhibited a distinct shift in the population distribution of activities (Figure 3-16).  
Unlike the original droplet population, the sorted DNA shows a bi-modal distribution of activity 
with a shift in the frequency of more active samples, suggesting two core activity profiles within 
the population – that of the original and more active ATA117 enzyme, and that of the weaker 
S17P.  This suggests enrichment occurred for the more active form of the transaminase gene  
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Figure 3-16: Rescreen data from the re-expression of hits from the S17P library 
Library activity distribution before (A, B) and after (C, D) MADS enrichment.  MADS 
enrichment of the samples in the upper half of the figure results in a library of samples that 
reveal a bimodal distribution of activity in the re-screen.  This is additionally supported by 
sequencing data showing a higher number of wildtype mutations in the second library than in the 
first. 
 
from the original droplet population, but that this enrichment was imperfect – we still captured 
less active variants in the hit population, likely due to the relatively wide spread of the droplet 
signals.  The enrichment seen in the re-expression of the enzyme samples was further supported 
by sequencing data showing that more than 25% of the samples contained the wildtype sequence 
after MADS sorting.  
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3.6 Challenges and Prospects for the MADS system 
The results described above suggest that MADS is capable of enriching a population of 
enzymes for samples outperforming the parent enzyme, but there remain challenges to the full 
implementation of this work, and opportunities for further improvement to the workflow and 
system throughput.  In particular, single droplet sequencing has revealed that both fidelity and 
sample purity during digital DNA amplification was a challenge in this work, and there are 
additional challenges associated with the assessment of the substrate amine, rather than the 
product formation in the reaction.  Ongoing work with the enzyme assay conditions suggests that 
reaction timing, substrate concentration, and reaction conditions may all be optimized to yield 
better MADS sorting conditions with this transaminase system.  In the following section, we 
outline the key areas of improvement and ongoing work to address the difficulties that we have 
encountered thus far. 
3.6.1 Single Droplet Sequences: Multiple Mutations and Background Signal 
One clear concern stemming from the single droplet sequencing of the S17P library is the 
introduction of unexpected mutations to the library sequences between library quality control 
testing and reagent addition of PCR amplified DNA droplets to droplets of ivTT.  Nine of fifteen 
sequences read in the pre-screen single droplet sequencing (60%), and 82 of 354 (28%) read in 
the post-screen DNA sequencing exhibited the presence of mutations that were not present in the 
original library pool. There are several possible causes for this change that will need to be 
investigated, as the unintentional addition of diversity in the library pool could prove problematic 
when screening for specific mutations.  The first possible source of mutation in the droplets is 
the polymerase used to amplify the samples.  Current PCR protocol utilizes a mixture of a high 
fidelity polymerase (Q5) and BioRad’s proprietary polymerase for digital PCR.  Polymerases for 
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digital qPCR need to have 3’  5’ exonuclease activity in order to degrade detection probes, and 
there is no requirement that these polymerases maintain high fidelity because their main purpose 
in these reaction mixtures is to produce as much product for detection as possible.   If this 
polymerase is one of low fidelity, it could be introducing mutations into the sequences in the 
droplets during the PCR process. Notably, the vast majority of the unexpected/untargeted 
mutations observed in this work are single nucleotide mutations, which may be a result of 
promiscuity in the polymerase mixture.  Ongoing investigation into the deactivation of this 
polymerase seeks to eliminate this potential variable from the droplet PCR process. 
Another possible source of these mutations in the digital PCR process is the presence of 
SYBR green in the PCR reaction mix.  Commercial SYBR Green is sold at “10000x” 
concentration, which appears to be approximately 10 mg/ml, a common dilution of stock DNA 
dye solutions like ethidium bromide
125
.  The final SYBR Green concentration used in this work 
is a dilution in the PCR master mix to 2.5x (0.2 mg/ml), and it is possible that at this 
concentration, the intercalation of dye into DNA as it is replicated can prove mutagenic.  With 
single droplet sequencing possible, it would be valuable to investigate various SYBR Green 
dilutions for mutagenic effects, as high concentrations of the dye and its degradation byproducts 
have been linked to PCR failure in the past
123
.  
 A third potential culprit lies in the number of cycles of PCR performed during digital 
amplification.  High numbers of cycles have been associated with the introduction of side-
products in PCR, and the digital protocol utilizes 40 rounds of amplification to generate DNA in 
the droplets.  While gel separations of the PCR amplified DNA in droplets do not show 
significant secondary product bands,  It would be valuable to investigate this further to determine 
if fewer cycles result in a lower frequency of the uninitended mutations in the droplet sequences. 
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3.6.2 Enzyme Assay Optimization  
As can be seen in the section 3.5, the key challenge to using MADS to sort a library of 
transaminases lay in the identification of ideal screening and assay conditions.  Transaminases 
catalyze a reversible reaction, which means that even when running in the thermodynamic 
direction (as we do here) there is an equilibrium concentration past which the enzyme cannot 
convert more substrate into product.  In typical biocatalytic reaction optimization, additional 
enzymes
66,117
 or extraction steps may be used to remove products from a reaction and continue to 
drive product formation forward, but in the microfluidic context explored in this work, such 
strategies are not implemented.  This means that the reaction will run until it reaches this 
equilibrium,  so the assay must be built such that it takes the encapsulated enzyme a significant 
amount of time to do so, giving plenty of opportunity for a faster enzyme to distinguish itself 
from the slower.  One possible solution lies in the addition of secondary enzymes that remove 
product in a secondary reaction, to drive the first reaction forward.   
3.6.2 Effect of Time on Unquenched Reactions 
Reactions performed through the addition of DNA to droplets of ivTT are not quenched.  
This presents a challenge, in part because it means that reaction reads are dynamically changing 
as the screen progresses (Figure 3-11, 3-12).  While we have partially addressed this by adding a 
running reaction positive control to select samples of interest, doing so has introduced its own set 
of challenges.  We have seen this in particular when reading the reaction in droplets over 
extended time periods.  Figure 3-17 shows the changing concentration of droplet samples over 
the course of a 9 h read starting within one hour of DNA addition to droplets of ivTT containing 
10mM substrate.  Sseveral hours of reaction time are necessary to see a difference between the 
positive DNA expressing samples, and the negative samples, and that the ability of the MS to 
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Figure 3-17: Time course read of wildtype ATA117 in droplets 
 A 9-hour run of the MADS system at 10 mM amine monitoring the activity of the wildtype 
ATA117 enzyme reveals the difficulty of screening an active enzyme reaction in microfluidic 
droplets.  As time progresses, the WT enzyme is expressed and begins to reduce substrate 
concentration within the sample droplets.  Screening an unquenched reaction such as this 
requires screening with a dynamic threshold for hits, and the screen becomes more robust as time 
progresses, making the selection criteria applied to the later portion of droplets inherently more 
robust than that applied to the earlier portion.  By quenching the reaction, all droplets would be 
screened under the same conditions with the same criteria, regardless of when they are assessed. 
 
 distinguish these changes will increase as time progresses. Quenching the reaction could allow 
us more freedom to screen all samples under the same conditions, and would reduce the need to 
use a dynamic thresholding technique. 
3.6.3 Reaction Monitoring and Chemical Crosstalk 
One of the largest challenges to the success of this work has been the movement of small 
molecule substrates between microfluidic droplet samples. The rapid loss of distinct ketone 
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product signal in the droplets has led us to monitor this reaction by substrate loss, but this 
presents a significant challenge analytically.  The choice to monitor amine in the reaction means 
that the difference between a parent enzyme that converts 5% of the substrate and an evolved 
variant that doubles this activity is only 5% of the signal read.  Given typical signal RSDs of 5-
10% on the droplet MS, this is a significant challenge, because it requires us to find an enzyme 
and screening conditions in which the wildtype enzyme may convert enough substrate to be 
visible as distinct relative to the blank samples, but which leaves plenty of conversion (dynamic 
range) possible before a better enzyme reaches the equilibrium condition of the reaction.     
This is further complicated by chemical cross talk, which appears to happen with the 
substrate amine as well as the product ketone, albeit at a much slower rate.  This leakage feeds 
more substrate into active droplets from surrounding samples as the reaction runs, reducing the 
magnitude of separation between positive and negative samples.  A system in which a product 
that does not transfer between droplets is monitored would avoid many of these issues; a 2-fold 
increase in activity when monitoring production of a product is a 100% increase in signal, rather 
than a few percent decrease, even at relatively low conversion rates.  Monitoring product 
formation would more cleanly separate distinct enzymes from their parent sequence, and enable 
more accurate assessment of the relative activities of different enzymes. 
3.7 Conclusions/Impact 
Directed evolution is a labor, time, and resource intensive proposition, with the largest 
bottlenecks being the generation of libraries of enzyme samples, and the efficient screening of 
these populations.  Microfluidics offers the opportunity to rapidly generate large enzyme 
libraries in droplet format, and MADS enables label free screening of these libraries at 
unprecedented throughput.  In this demonstration we showed that a single researcher operating 
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the MADS system is capable of expressing and screening more than 2000 enzyme variants for 
rapid discovery, all in the course of a few days.  Including the library generation, sample 
preparation, screening, and sequencing, a full round of expression and selection may be carried 
out in just one week’s work.  Typical throughputs for directed evolution require a team of 
scientists to spend weeks of screening to achieve similar results.   
From the initiation of protein expression to the final MS assay, the full microfluidic 
workflow for directed evolution using MADS takes only 24-30 h of lab time for a single 
researcher.  In a conventional  round of enzyme evolution, a single SSM screen can take a team 
of 4 researchers 3-4 weeks to complete, while the MADS platform allows a single researcher to 
perform the same work in the course of a week.  Per-sample cost in MADS is reduced to $0.03 
per 30 nL sample.  If these reactions were performed in well plates at 25 µl volume (the 
manufacturer’s recommendation for ivTT reactions) a screen of 2000 enzyme variants would 
require 50 ml of ivTT and cost more than $45,000. 
High throughput mass spectrometry coupled with microfluidic sample processing enables 
rapid experimentation in protein engineering workflows.  This is an area of research that has 
traditionally relied heavily on time intensive molecular biology and LC based analytical 
workflows, which has limited the utility of the technique and slowed widespread adoption of 
biocatalytic synthetic approaches.  The time and cost savings of performing directed evolution in 
droplet samples offers the prospect of significantly more expansive enzyme screening campaigns 




Chapter 4: Insights and Future Directions  
 
4.1 Challenges and Opportunities for MADS and Droplet MS 
The work described in the preceding sections of this thesis has covered a broad range of 
microfluidic techniques and devices for the production, manipulation, and analytical assessment 
of microfluidic droplets and their contents.   While chapters 2 and 3 describe key milestones 
delivered from the design and preliminary application of the MADS system, this chapter seeks to 
(1) assess and address the key challenges and ongoing investigation in the implementation of the 
MADS system for the directed evolution of a transaminase, and (2) highlight the future of 
droplet based microfluidic systems, with an emphasis on future areas of exploration.  
4.1.1 Distinguishing populations of droplets   
There are two factors that play into the robustness of a screen and the ability of a screening 
technique to make an accurate determination of the validity of a hit, and these are intrinsic to the 
way we calculate the reliability of a screen with Z’ factor.  The first is the dynamic range of the 
screen – the distance between positive and negative signals, often expressed by the difference in 
signal means.  The second is the spread of the signals at any given concentration – the sample to 
sample variability.  The first of these may be improved by changing the concentrations of 
reagents loaded into the reaction, increasing the incubation time, or shifting the reaction 




While the calibration of the MS signal presented in chapter 2 showed that the mean response 
of the mass spectrometer to Amine 1 in ivTT was linear with respect to the amine signal, it also 
revealed that the relative variance of the signal increased with the increase in analyte 
concentration.  This is particularly evident when the 6 populations plotted in Figure 2-10 are 
plotted on a linear scale, rather than a log scale (Figure 4-1). 
Figure 4-1: Variability in droplet signal with increasing concentration 
The raw distribution of signal intensity for 225 droplets of ivTT doped with 6 concentrations of 
amine shows that the signal variation increases as the signal intensity increases. 
 
If the variance was similar at all concentrations, the relative standard deviation (RSD)of 
the signal would decrease with increasing signal intensity (concentration) and the minimum 
concentration change necessary to distinguish two populations of droplets would be constant 
regardless of signal intensity.  This does not appear to be the case.  This means that depending on 
the intensity of the signal, the magnitude of change in average signal necessary to distinguish a 
second population of samples will be different. 
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To explore this phenomenon further, it is valuable to consider (a) how we might define 
full resolution of two sample populations and (b) how the signal variance changes as a function 
of sample concentration and signal intensity.  To address the first of these, we can use the 
analytical description of resolution in chromatography as our guide.  In chromatography, peak 





where µ describes the mean value of a peak (usually expressed in retention time) and W 
describes the spread of that peak, as described by 2 full standard deviations in either direction 
from the mean.  A resolution of 1, therefore, is achieved when the separation between the means 
of two Gaussian peaks is equal to two standard deviations from the center of the first peak plus 
two standard deviations from the second.  In other words, when the 95% confidence interval of 
two peaks lie edge to edge, the two distributions are considered fully resolved (R=1).  If we use 
these criteria to evaluate populations of sprayed droplets, we can calculate the necessary 
concentration change for full 4σ separation by considering the mean and standard deviation of 
our samples from the calibration data from chapter 2. 
In Figure 4-2, we plot the mean and upper and lower 2σ values for the extracted ion counts 
reported for 225 peaks at 6 different concentrations.  The increase in upper and lower bounds for 
the Gaussian distributions of these signals is linear at these concentration ranges, and can be fit 
to a line that describes the relative increase in standard deviation (2σ)  expected from an increase 
in sample concentration.  Because this signal variation scales linearly with signal intensity, it’s 
possible to calculate the change in concentration (C) necessary to fully resolve two Gaussian 




Figure 4-2: Linear increase in droplet signal variation with mean signal intensity 
The standard deviation of signal from the droplet samples increases linearly with increasing 
concentration of amine in the sprayed droplets.  This linear trend can be used to predict the 
variability of a population of droplet samples given a sample concentration or mean signal 
intensity. 
 
For two droplet distributions to be fully resolved, the lower bound of the 95% confidence 
interval of one must be equal to the upper bound of the other.  Because the lower and upper 
bounds of the confidence intervals can be described by linear equations, we can define the point 
where the two theoretical distributions would reach a resolution of 1, YResolution, as a function of 
both the line describing the upper bound of signal variation and the  line describing the lower 
bound of variation such that 
𝑚𝑢𝑝𝑝𝑒𝑟(𝐶2) = 𝑌𝑅𝑒𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 = 𝑚𝑙𝑜𝑤𝑒𝑟(𝐶1) 
where C1 is the concentration of the population of droplets with mean signal µ1 and C2 is the 
concentration of the population with mean signal µ2.  Here, mlower describes the slope of the 
linear fit of the lower bound of the 95% confidence intervals of MS signal distribution and mupper 
describes the slope of the linear fit of the upper bound of the 95% confidence interval (Figure 4-
3). Rearrangement of this equation gives us the relationship between the slope of the lines 
describing instrumental variation and the minimum concentration difference between two fully 









For the calibration performed in chapter 2 (Figure 2-10) and the linear fits shown in Figure 4-
2, this ratio is 1.34, and tells us that for a given concentration in a droplet to be fully 
distinguishable from another, the second population must have 1.34 times the analyte 
concentration of the first. 
Figure 4-3: Linear increase in droplet signal variation with mean signal intensity 
An annotated re-creation of the plot in figure 3 shows how the linear fit of the 2σ upper and 
lower bound on the calibrated droplet concentrations may be used to predict the minimum 
concentration difference necessary to create two populations of droplets whose distribution of 
signals are baseline resolved. The difference between C1 and C2 may be calculated by finding 
these values at Y=YResolution for the linear fit of the upper and lower bound of the 95% confidence 
intervals of the calibrated droplet concentrations.  This helps conceptualize that the data 
distribution is going to scale linearly with concentration and that the difference in concentration 
necessary to resolve two populations of droplets is concentration dependent. 
 
4.1.2 Signal Variation in Expressed Enzyme Samples 
We can use the linear relationships between signal variation and the signal intensity 
calculated using the calibration data in Figure 2-10 to predict the signal variation for a signal 
with given mean intensity µ.  Comparing the distribution calculated using this calibration data to 
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real-worked data collected while reading enzyme expressed in microfluidic droplets allows us to 
compare the signal variation observed during the enzyme assay to the expected signal variation 
from the instrument and determine if there is a significant difference between the two.  When 
this is done for the first 100 samples expressing enzyme DNA and the first 100 blank samples of 
the data from Figure 2-12, the calibration-predicted signal distribution very closely matches and 
predicts the observed distribution (Figure 4-4).  A t-test comparison of the observed and the 
calibration based predication of signal distribution reveals no significant difference (P>.05) 
between the distribution of signal intensity seen in the actual enzyme expressed in droplet 
samples, and the predicted instrumental variation at that same signal intensity.  
Figure 4-4: Instrumental signal variation predicts the spread of droplet data 
When the calibration data from the ivTT calibration is used to predict the distribution of signal 
intensities at the mean intensity of the first 100 samples from the ivTT expression experiment 
shown on the right, the predicted data distribution closely resembles that of the observed data, 
suggesting that the variation seen during expression is largely predicted by instrumental 
variation. 
 
This result suggests that the observed variation in droplet signal is largely explained by 
instrumental variation, rather than concentration variation within the population of droplets 
expressing transaminase.  If the expression of transaminase was increasing the variability of the 
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droplet signals, we would expect the signal distribution to be significantly different, but the t-test 
tells us that our null hypothesis – that the two distributions are equivalent –cannot be rejected.   
4.1.3 Chemical Transport between Droplets   
Chemical transport between microfluidic droplets is perhaps the single largest hurdle to 
the field of droplet microfluidics.  Fluorinated oils and surfactants were initially introduced as 
omniphobic continuous phases to better contain droplet analytes
95,126
 but researchers have 
observed chemical crosstalk between stabilized droplet samples, especially when stored in bulk. 
As the transfer of droplet analytes appears to be largely confined to small molecule analytes, this 
presents a significant barrier to the implementation of systems such as MADS for HTS of small 
molecule production.   
In order to better understand the factors that give rise to droplet crosstalk, several groups 
have investigated molecular retention in droplet emulsions using fluorescent 
detection
94,95,109,110,127-129
 Buffer pH, fluorophore solubility, analyte hydrophobicity, and micellar 
transport have all been proposed as contributors to fluorophore loss both into the surrounding oil 
phase and into neighboring droplet samples. However, no definitive mechanism of molecular 
transport is widely agreed upon. Solutions to this issue are still in their infancy, but a number of 
potential options have been proposed and appear to improve retention in some contexts.  
The addition of bovine serum albumin or sugars to droplet solutions has been 
demonstrated to increase fluorophore containment in a few examples,
95,128
 likely thorough the 
improvement of fluorophore affinity for the droplet phase and the disruption of fluorophore 
affinity for the surfactants used to maintain droplet separation.  The modification of fluorophores 
with permanently charged groups, as well as the use of analytes with permanent charge, appears 
to discourage chemical loss between samples.
129
  Indeed, the three analytes used to monitor and 
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identify droplet populations in the MADS system, neostigmine, carnitine, and chlorocholine, 
were all selected because they are quaternary amines, with permanent positive charge.  This 
permanent charge made them easy to detect, and no chemical transfer was observed between 
them, despite extended incubation and operation times with droplets in close contact (Figure 4-
5).  Nanoparticle and dendridic
130
 surfactants have also been shown to reduce micelle formation 
and discourage surfactant mediated transport, leaving carrier phase solubility as the only driving 
force for chemical loss
108,109
  
Ultimately, significant investigative work still needs to be done in order to rigorously 
define and address the true driving mechanisms behind chemical transport between droplets.  
Fortunately, droplet mass spectrometry provides a unique opportunity to investigate molecular 
transport in droplet systems.  Continuous infusion of droplets stored in bulk has enabled us to  
Figure 4-5: Comparison of analyte retention within droplets 
Raw MS traces are shown for a 5-hour run of droplet mass spectrometry reveals the gradual drop 
in signal of amine 1 (upper trace) while the signal of chlorocholine (lower trace) remains at a 
consistent intensity.  In this experiment, only 20% of samples contained chlorocholine, and more 
than 20% of samples contained amine 1 with no active enzyme, but all amine signals dropped 
over the 5 hour run, suggesting the leakage of amine from high concentration droplets to low 




monitor reaction progress over time, and we’ve observed the leakage of small molecules in these 
systems over the course of extended experiments as well (Figure 4-5).  Prior to the advent of this 
label free assessment technique, most of the analytes investigated for retention in droplet samples 
were fluorescent materials that could be tracked with optical detection.  Mass spectrometry has 
allowed us to track the movement of materials across droplets, and offers a unique opportunity to 
characterize the nature of chemical transfer, and ultimately develop better, more broadly useable 
surfactant materials.  This will be critical to the potential for systems such as MADS to be 
broadly useable across applications and chemical systems 
4.1.4 Quenching Reactions in a Microfluidic System 
In typical enzyme screening workflows, reactions are quenched in order to provide an 
identical basis of comparison for all samples assessed.  This typically requires the addition of 
reagent to rapidly denature proteins in solution and stop the activity of the enzyme.  In our 
microfluidic workflow, we opted not to perform this step and instead assessed reactions as they 
ran in real time.  This creates two potential issues – if some proteins are expressed more rapidly  
than others, they may appear to be more active in this system simply due to this, and because the 
reaction is running in real time, selection thresholds must adapt as the screen is running to 
compensate for the expected activity of the average sample.   
The first of these two issues is one that is common to protein engineering workflows 
performed in cells.  Expression hits that are more easily produced by cells can appear to be more 
active than their less easily expressed counterparts.  Fortunately, ivTT is unlikely to have this 
issue, because the expression rate of DNA in vitro should be relatively similar across all variant 
DNA where the difference between two DNA variants is just a single codon, and cytotoxicity is 
a non-issue.  Variability in the start of the expression process also appears to have a relatively 
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minor effect on signal spread in the droplets.   Even when expressing the same DNA across all 
droplets (such as was done in figure 2-12) where each droplet received DNA at a different time 
over the course of reagent addition, the signal variability does not seem to be greater than what 
would be expected from instrumental variation alone.   
The second of these challenges is perhaps more concerning -  in an unquenched reaction, 
hit identification is complicated by the activity of the samples throughout the screen.  If we 
choose to assess all samples based on the same thresholding criteria (as was done in the original 
testing of the MADS system), samples that are read later in the screen have more time to react, 
and therefore are more likely to achieve the criteria necessary for selection and recovery.  This 
means that we risk type 2 errors (collecting false negatives) for the first half of the screen, and 
we risk type 1 errors (collecting false positives) in selection for the second half of the screen 
(Figure 4-6 A).  In the case of the dynamic thresholding used in MADS, we chose to select 
samples based off of a moving threshold (determined from the parent enzyme activity) to 
minimize the chance that we would collect a false positive or negative sample.  This significantly 
reduces the amount of screening time during which we risk a false selection, but does not fully 
resolve the issue because the threshold activity will eventually reach the maximum activity of the 
screen, after which it cannot differentiate a hit.   In this setup, the dynamic range of the reaction 
(the distance between a positive and a negative sample) changes as a function of time.  Initially, 
the dynamic range is small and the activity difference between a parent enzyme and an improved 
variant is low.  With time, the activity of the improved variant becomes distinct from the parent, 
but as activity slows and the enzyme reaches static equilibrium in the reaction, the parent enzyme 
catches up and the distance between the parent and the faster enzyme falls to zero (Figure 4-6 B).  




Figure 4-6: The benefit of a quenched enzyme reaction 
Theoretical plots of enzyme activity in unquenched reactions reveal the limitations of (A) static 
thresholding for activity selection in an unquenched reaction, (B) adjusted thresholding for 
activity selection in an unquenched reaction (as performed in the MADS system), and (C) 
quenched reaction screening with static thresholding.  In a quenched reaction, the difference 
between a positive and a negative variant is always the same, and selection may be undertaken 
without the risk that changing enzyme activity will affect the screening results.  In all three plots, 
ideal screening conditions are highlighted by green shading, revealing that only the quenched 
reaction condition enables error-free screening for the entirety of the screening period.  Type 2 






the confidence with which hits are chosen will be highest in the midpoint of the reaction, and 
will fall off preceding and following this point. 
In a quenched reaction, the risk of a false positive or negative selection is independent of 
the screening time, and the dynamic range is static.  By quenching the reaction at the time when 
a positive and a negative control sample are most distinct, we maximize the selection window’s 
range, and we enable the reaction to be screened in perpetuity.   Figure 4-6 gives a theoretical 
comparison of all three selection methods.  Due to the additional complexity of quenching 
microfluidic reactions in droplets, we chose to use the second method for our screen, but the 
relatively high variation (RSD was between 6% and 9% for the calibration in Figure 2-10) in 
signal for droplets of the same concentration limited the screening window to the middle period 
of the reaction.  Under this mode of operation, false negative and false positive selection became 
more likely early and late (respectively) in the screen.  Given the necessity of a screening period 
of several hours to achieve the library coverage desired in a full SSM screen (10
3
 enzyme 
variants with at least 3 replicates), the MADS system currently benefits from screening slower 
reactions and wider dynamic ranges. 
One solution to this challenge is to perform reagent addition a second time in the 
microfluidic workflow, after the addition of DNA to individual droplets, and after the expression 
of that DNA.  This would be possible to implement using picoinjection
131
 ( or K-channel 
picoinjection
132
) reagent addition, which we pursued early in this project as a potential method of 
addition to microfluidic droplets.  In pico-injection based reagent addition, droplets are re-
injected and flowed past a perpendicular channel filled with aqueous reagent connected to a 
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pressurized vial.  By closely matching the applied pressure in this reagent stream to the Laplace 
pressure of the oil and water interface of the injection channel and the cross flow, the interface  
  
Figure 4-7: K-channel reagent addition enables scalable addition to all droplets 
K-channel architecture
132
 on a microfluidic device may be used to add reagent from a continuous 
stream to a series of re-injected droplets as they pass the picoinjection region on the device. In 
(A), a schematic of a device for the processing of 160 pl droplets is shown.  The device is 
fabricated to 50 µm depth with 50 µm channels and a 10 µm interface between the reagent cross 
flow (V-shaped channel) and the droplet stream (horizontal channel). (B) Data from 
experimentation with the device shows that as the pressure applied to the reagent cross flow 
rises, the volume added to the droplet rises.  Such a system would allow the chemical quenching 
of in-droplet reactions after expression and activity assay, and may represent an opportunity to 





may be maintained without producing any droplets of reagent in the cross flow.  When aqueous 
droplets flow past this architecture, a high voltage electric field applied to parallel electrodes on 
the device destabilizes the surfactant which otherwise prevents the droplet from merging with the 
added reagent, and allows the injector to add reagent to the droplet.  We initially implemented 
such a system for reagent addition during the early work on the MADS project, using the K-
channel architecture to add up to 130 pl to droplets of approximately 160 pl in a device designed 
with 50 µm square channels (Figure 4-7). 
One of the challenges to implementation in this sort of system is the stability of the 
oil/water interface in a pico-injection system.  Because the pressure of the system fluctuates as 
the droplets flow through the channel,
133
 the interface between the oil and the aqueous solution in 
a picoinjector must move to adjust.  To minimize this movement and avoid allowing the solution 
to bulge too far out into the cross flow and create satellite droplets in the microfluidic system, the 
Laplace pressure differential across this interface needs to be high.  Because Laplace pressure of 
the oil/water interface scales inversely with the radius of curvature of that interface, the 
connection between the two channels must be kept as small as possible to ensure as small and 
highly curved of an interface as possible.   While this is relatively easy to do at smaller 
fabrication scales, as the channel size increases to accommodate larger droplet volumes, the 
stability of the picoinjector decreases, and its sensitivity to minor changes in pressure on the 
reagent vial increases.  This means that minor changes in applied pressure, liquid height in the 
vial, and vial height relative to the device can have large scale effects on the consistency of the 
reagent addition.   Figure 4-8 shows a series of images of the output of a scaled up reagent 
addition device operating over a 25 minute period.  This device scaled channel width to 100 µm 
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Figure 4-8: Drift in K-channel operation at nanoliter scales 
(A) K channel geometry is used to add 3 nl to a 3 nl droplet in continuous flow.  This scaled 
device is capable of processing droplets that are on the same volumetric scale as the samples 
screened in MADS, and holds the potential for use as a reaction quenching mechanism for assays 
carried out in droplets.  However, in order to fully implement such a system, it will be first 
critical to address the drift in added volume observed over extended operation of the device (B).  
This variation is likely due to the large (100 µm) interface between the cross-flow and the 
droplet injection channel, which is sensitive to relatively small pressure changes in the system 
during operation. 
 
and height to 100 µm.  This 400% increase in channel cross sectional area was sufficient to take 
3 nL droplets and more than double their volume (up to 8nL) but the channel expansion made 
stable operation of the picoinjection platform much more challenging.  The longer the device 
operated, the more the vial holding the injected liquid drained.  As this occurred, the effective 
pressure on the injected reagent drops and the volume injected fell in tandem.  This may be 
possible to buffer against by using high resistance (back-pressure) fluidic lines or larger volume 
source vials, but more investigation and optimization will be necessary for the implementation of 
a picoinjection device for larger, 30 nL reaction droplets.  Alternatively, digital PCR, fluorescent 
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sorting, and  ivTT expression could be scaled down to pl volumes, and the resulting library could 
be quenched at picoliter scales.  The resulting material could then be diluted in larger droplets for 
analytical assessment.  
4.1.5 Data density and MS Cycle Time 
Another key challenge in the MADS system is the data acquisition rate of the mass spectrometer.  
Under current operating conditions, the minimum dwell time for each ion channel on the mass 
spectrometer is 0.005 s.  This means that the instrument takes 200 reads per second, divided over 
4 channels for a total of 50 data points per channel per second.  At current flow rates and oil 
spacing, droplets are sprayed every 1.4 s, and spaced with oil at a 10:1 ratio.  This means that 
droplets dwell at the tip for 0.13 s, allowing approximately 25 points to be taken across the four 
MS channels.  This means that at the most, each channel gets approximately 6 data points across 
the droplet (Figure 4-9).  The microcontroller running the MADS system extracts the maximum 
data point read during the course of a single peak and utilizes this data to make a sorting 
decision, but this means that the droplet MS is sensitive to variations in signal intensity that 
occur over the course of those 6 samples.   
Faster sampling rates in the mass spectrometer may help combat some of the variability 
across droplet reads, especially with the implementation of average peak height detection and 
reporting, rather than maximum peak height detection.  Slowing the flow rate, and reducing the 
spacing of droplets in the microfluidic system may also help this, as doing so would allow the 
droplet volume to be detected over a longer period of time, and provide greater numbers of 
samples across a droplet.  Improvement in the instrument sampling and scanning rate is certainly 
feasible.  Recently, Waters collaborated with  Kempa et al
63
 to read as many as 30 droplets per 
second on a mass spectrometer.  Ultimately, improvements in instrumentation and MADS 
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technique should be capable of yielding reliable, data-rich reads of nanoliter and picoliter scale 
droplets, enabling MADS with greater reliability. 
 
Figure 4-9: Sampling frequency on an Agilent 6120B monitoring 4 ions 
A sample trace from 30 nl MADS droplet screening shows two droplets read by the mass 
spectrometer.  Individual signal reads are marked to highlight the relatively low number of reads 
collected across individual droplet samples.  In this case, only 5-6 reads are taken across a 
droplet.  This limits the analytical robustness of MADS.  Faster sampling mass spectrometers 
and the use of average peak height rather than peak maxima to assess droplet concentration may 
improve the robustness of the MADS technology. 
4.1.6 DNA Loading 
One ongoing challenge to the MADS system is the isogenic loading of droplets with 
DNA for expression.  Early on in our work, we proposed the use of one-bead-one-gene libraries, 
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and we optimized microfluidic devices for rapidly sorting droplets for those with encapsulated 
magnetic beads (Figure 4-10). This device allowed us to generate and sort 50 µm (65 pl) droplets 
containing 10 µm magnetic beads (Spherotech) at greater than 500 Hz, rapidly enriching for 
singly-encapsulated beads in droplets.  The original intention was to functionalize these beads 
with DNA and then pair them with ivTT for expression, but we found the digital PCR process to 
be more amenable to early implementation, and ultimately did not pursue this system.  However, 
DNA functionalized beads used in ivTT expression have recently been reported for the droplet 
based expression of an oxidoreductase, 
134
 and have been demonstrated in 30 nL droplets. 
The use of microbeads for enzyme expression could be a significant improvement 
relative to single droplets of amplified DNA for several reasons.  First, the microbeads cannot 
merge and combine with one another like droplets may, reducing the potential for singly 
captured genes ending up mixing prior to addition to ivTT.  Additionally, microbeads are easier 
to capture, and could be separated out into individual wells or locations after sorting, maintaining 
 
Figure 4-10: Magnetic sorting of 65 pl droplets 
A micrograph and data from 9 experimental runs of a magnetic sorting device for 65 pl droplets 
containing 10 µm magnetic beads.  Upstream, droplets are generated from an aqueous 
suspension of magnetic beads in a 60 µm x 60 µm flow focusing cross (SU-8 patterning height 
50 µm).  Droplets flow into a 200 µm sorting channel located 200 µm from a permanent N42 
neodymium magnet.  A tapered, offset pillar array enables droplets pulled slightly (~10 µm) off 
center by the magnetic field to be sorted into one of two exit channels, enabling rapid enrichment 




the digital character of the hit material, even after de-emulsification.  There remains significant 
potential in the development of the MADS system around bead-based gene libraries, and much 
of the groundwork for this has previously been laid. 
4.2 Alternate Applications for the MADS Platform   
MADS screening offers an opportunity for rapid, label free screening at the nanoliter 
scale.  In this thesis work, we have applied this system to performing directed evolution; 
however, we envision the MADS platform to be amenable to a broader range of screening 
methods as well.  Recently, FADS based screening has been implemented in the high throughput 
screening of DNA encoded, bead bound libraries of small molecules.  DNA encoded libraries are 
gaining popularity in discovery chemistry as potential solutions to scale down the size and 





 techniques coupled with DNA oligo construction on the same 
scaffold, a library of small molecules may be constructed such that each unique chemical is 
associated with a genetic sequence.  In a recent report, Cochrane and coworkers created a DNA 
encoded library of small molecules on solid support (microbeads) to screen for enzyme 
inhibitors
85
.  The resultant beads contained both a DNA oligo coding for the synthetic split and 
pool sequence, as well as the bound small molecule.  Beads were encapsulated into droplets of 
enzyme and substrate, and upon UV irradiation, the bead-bound small molecule could be 
released from the bead’s surface and into the droplet within.  If the activity of the probed enzyme 
was reduced by the released small molecule, it could be detected by a fluorescent sorting device 
as a decrease in the relative fluorescence of the droplet, leading to capture of the droplet.  
Following sorting, beads were sequenced to reveal the small molecule library members 
responsible for this inhibition.   
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One potentially attractive direction for the MADS platform is the performance of similar 
small molecule screens for discovery chemistry.  MADS provides the distinct advantage of being 
able to probe virtually any reaction that may be detectable by MS, eliminating the need for a 
fluorescent product.  Upon generating a DNA encoded library on small magnetic beads, similar 
small molecule dosing could easily be achieved for the droplets entering the MADS device.   
Figure 4-11: Magnetic biasing to recapture beads in split 100 pl droplets 
This series of images shows a droplet splitting device dividing a droplet containing a 10 µm 
magnetic bead (highlighted by black arrows).  Because the split is performed in close proximity 
(200 µm away) to a permanent magnet, the bead is biased into the upper channel every time.  
This technique could be used to recover a bead containing a DNA barcode from individual 
droplets. 
 
These droplets could easily be sorted based on bead content using our existing magnetic bead-
based droplet sorter. The bead can subsequently be recovered using magnetic field assisted pull 
down during the splitting step of MADS (Figure 4-11).  This could assure that the bead would 
not be lost to the mass spectrometer, and hit beads could be recovered and sequenced asdescribed 
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by Chochrane and coworkers.  A MADS system such as this could potentially screen more than 
100,000 library members in a week, at the cost of a few milliliters of reagent and a few 
miligrams of magnetic beads.  Such a system would be easily scaled to screen the same library of 
bead bound compounds against hundreds of targets, with no modification to the system apart 
from the input reaction mixtures containing the target enzyme system. 
4.3 Improving the throughput and sensitivity of droplet MS   
NanoESI-MS (nESI-MS) would be a valuable tool to apply to the MADS system.  Recent 
work from our group has demonstrated nESI-MS of droplets in the picoliter range, and at these 
low flow rates and microscopic spray tip dimensions, droplet electrospray has proven to be far 
more sensitive, achieving low micromolar to nanomolar limits of detection.
61
  In addition, nESI-
MS has been demonstrated at throughputs up to 10 samples per second and could prove readily 
amenable to higher throughput screening. 
In order to incorporate nESI-MS with MADS, device scale down might be necessary to 
produce smaller sample droplets that may be rapidly introduced into the MS spray tip.  At 
smaller droplet scales, more droplets may be infused at the same flow rates, and nanoliter per 
minute flow rate ranges may still be used to sample multiple droplets per second.  To perform 
MADS at these smaller scales, each of the devices for the MADS unit operation would require 
scale down to dimensions in the 25-50 µm range (channel width) from their current dimensions 
to accommodate the smaller droplet sizes.  Fortunately, many of the MADS component devices 
were in fact initially developed for this scale of droplet manipulation, and these existing designs 
could be easily applied to testing nESI-MADS.  MADS at picoliter scale is certainly within reach 
in the near term; indeed, the company Sphere Fluidics, based in the UK, is currently in the 
process of developing one such system. 
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4.4 Future Directions for Droplet Infusion   
The MADS workflow provides many key advantages in terms of reduced sample usage 
and improved assay throughput, but there will inevitably be some reactions that remain better 
suited to well plate formatted screens.  Complex biochemical and organic synthesis reactions 
with numerous reagent addition steps are difficult to perform in droplets, as each microfluidic 
unit operation introduces added variability in droplet size, contents, and stability.  As such, 
automated workflows that require minimal manual manipulations appear to be better suited to 
these droplet strategies.  Moreover, in several applications, there is significant value in using 
droplet analysis for rapid assessment of well plate samples, as demonstrated by Diefenbach et 
al.
77
  In such instances, continual sampling of droplets from a well pate into a mass spectrometer 
is of significant interest.  To enable continuous sampling, there are two strategies that we have 
preliminarily investigated and which would benefit from dedicated efforts for implementation.  
4.4.1 Droplet Infusion Using Peristaltic Pumping 
From a setup standpoint, one of the simplest ways to achieve continuous infusion into a 
mass spectrometer involves using a flow-through pumping system, such as a peristaltic pump.  
This would allow samples to be simultaneously pulled from a well plate and pushed onto a mass 
spectrometer in continuous flow, without the need to disconnect and reconnect tubing from 
sampling to infusion (Figure 4-12).  This was preliminarily investigated using a Gilson Minipuls 
peristaltic pump to infuse samples onto a microchip capillary electrophoresis setup.   In this 
setup, a Gilson Minipuls pump operating at 1 RPM  was used to withdraw ~20 nL samples of 1 
µM “SDHA,” a short peptide derived from succinate dehydrogenase 
(5FAMGGQSLK(succ)FGKG).
51
 These droplets were pulled from a wellplate into 360 µM OD, 
150µM ID teflon capillary, which was in turn connected to the inlet of the 250 µM ID PVC  
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Figure 4-12: Peristaltic sampling of microfluidic droplets from a well plate 
(A) The experimental setup for a preliminary test of peristaltic sampling from a well plate. A 
peristaltic pump was used to pull nanoliter samples from a well plate containing blank and 
fluorescent aqueous samples onto a Teflon capillary.  These samples are drawn through the 
flexible tubing of the peristaltic pump, and then exported off of this tubing into Teflon capillary.  
This capillary may then be set up to transfer the droplet samples into a device for analytical 
assessment.  In the case of the proof of concept work shown here (B), droplets containing a 1 µM 
solution of the peptide 5FAMGGQSLK(succ)FGKG were introduced into a microchip CE 
system.
51
 Each sample droplet was followed by four wash droplets, and 5 samples were read 
each minute using LIF detection of the peptide after a 0.25s separation on the microchip CE 
device. Peristaltic sampling offers the opportunity to perform continuous flow infusion of 
samples from source to detection. 
 
tubing fitted to the peristaltic pump.  As the pump operated, an XYZ positioner delivered the 
trailing end of the capillary into wells on a plate of samples covered with a layer of  
perfluorodecalin oil.  Droplets were pulled up from the plate as the positioner moved from well 
to well, separated by carrier oil.  These droplets were then transferred through the pump tubing, 
and out into another short length of Teflon capillary running to a microfabricated CE chip.  
Preliminary data suggested that samples could be infused and cleared from the system every 15s, 
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suggesting the potential to use the same system to infuse droplets into a mass spectrometer 
instead. 
The largest hurdles to the implementation of a peristaltic pump sampling system are 
likely to arise from complexities in the surface chemistry of the peristaltic pump tubing and the 
pulsatile nature of peristaltic pump flow.  Peristaltic pumps rely on deformable tubing in the 
rotor region to drive flow through the system.  This tubing is often made of materials like 
polyvinyl chloride (PVC) that can withstand repeated deformation without wear, and these 
materials are more susceptible to analyte retention and sample-to-sample carryover than 
fluorinated Teflon tubing.  However, carryover can be minimized through the use of periodic 
wash droplets, and the simplicity of such a setup might outweigh the drawbacks of potential 
sample carryover.   
4.4.2 Continuous Droplet Infusion Using Pressure or Vacuum 
Another possible alternate method for rapid, continual sample introduction to the MS is 
to use pressure or vacuum driven flow to continually infuse samples onto the mass spectrometer.  
Pressure driven flow requires the pressurization of a sealed container holding the sample, which 
could prove challenging to implement safely.   However, by pressurizing the headspace above a 
well plate and running sampling capillary from this pressurized well plate the MS source, 
continual flow of droplets to the MS could perhaps be achieved. This sort of setup might be 
possible using existing technologies. For instance, by setting up an XYZ droplet sampling 
system in a glove box at elevated pressures and running the sampling line through a side of the 
glove box, continuous positive pressure could be applied to drive flow from a well plate of 
samples to analytical assessment. 
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Perhaps more simply, we can take advantage of the reduced pressures at the mass 
spectrometer source to draw in samples in for analysis.    This has recently been demonstrated in 
preliminary work with an Agilent 6120B mass spectrometer using a CE-MS source connected to 
60 cm of 360/150 teflon capillary.  Using the same plug flow mass spectrometry conditions 
described in 3.2.3, plugs of enzyme reaction were infused into the mass spectrometer for analysis 
using nothing more than the vacuum draw of the source region itself.  32 samples were infused 
into the mass spectrometer in 5 min by manually dipping the trailing end of the Teflon capillary 
connected to this CE-MS source into wells on a wellplate.  By alternating between wells of oil 
and wells of sample, we were able to avoid sample to sample contact in the capillary, clearing 
out each subsequent sample with a plug of oil (Figure 4-13).  This technique would be simple to 
implement for rapid assessment of nanoliter scale plugs from a multiwell plate, and could easily 










Figure 4-13: Vacuum driven infusion of samples onto a mass spectrometer 
Facile sampling to a mass spectrometer is achieved on nanoliter scale plugs of ivTT reaction mix 
using only the negative pressure in the source of an Agilent 6120B to drive flow.  Here, one 
enzyme variant is assessed in each cluster of samples (4 reactions, assessed at 1 h time points for 
8 h) for the transamination of amine.  The first two samples show no activity for the 
transamination, but the second two show rising signal from the ketone product of the reaction. 
4.5 Conclusions 
High throughput screening drives discovery in the field of chemistry.  Droplet 
microfluidics offers a unique opportunity for laboratory miniaturization and automation in ultra-
rapid screening workflows, but has largely failed to deliver on its promise over the last decade, 
largely due to limitations of analytical assessment in droplet systems.  With the expansion of 
microfluidic analysis into label free detection via mass spectrometry, droplet microfluidics is no 
longer confined to detection on florigenic assays, and is now capable of application across a 
broad range of systems.  We’ve demonstrated one such application – mass spectrometry based 
sorting of microfluidic droplets for directed evolution – and we anticipate continued 
development in the years to come as the versatility of sub microliter analysis via droplet mass 
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